Intestinal Research

Original Articles

Tumor

Does the size of the cold snare affect the outcome of cold snare polypectomy in the colon? A KASID prospective multicenter study: Seongwoo Choi, Jaeyoung Chun, Geunhyuk Choi, Yoojin Lee, Taegeun Gweon, Yunho Jung; Intest Res 2026;24(1):76-83. Published online January 28, 2026; DOI: https://doi.org/10.5217/ir.2025.00189

Abstract PDF PubReader ePub: Background/Aims
Cold snare polypectomy (CSP) is recommended for colorectal polyps <10 mm; however, the impact of snare size on clinical outcomes remains unclear. This study evaluated the efficacy and safety of 10-mm and 15-mm snares for CSP of small colorectal polyps.
Methods
In this prospective multicenter study, patients with 4–10 mm non-pedunculated polyps underwent CSP with either a 10-mm or 15-mm snare. Both snares had identical wire thickness and hexagonal loop design. The primary outcome was histological complete resection rate (CRR). Secondary outcomes included adverse events and technical parameters.
Results
In total, 182 patients were enrolled (10-mm group: n = 92; 15-mm group: n = 90). Baseline characteristics, including age, sex, polyp size, morphology, location, and pathology, were comparable between groups. Histological CRRs were 90.2% in the 10-mm group and 91.1% in the 15-mm group (P= 0.483). No significant differences were observed in the presence of submucosal tissue within specimens (P= 0.523), iatrogenic ulcer size (P= 0.532), hematoma occurrence (P= 0.391), or intraprocedural bleeding requiring hemostasis (6.5% vs. 5.6%; P= 0.974). No cases of delayed bleeding or perforation were reported. Logistic regression analysis identified iatrogenic ulcer size > 8 mm as an independent predictor of complete resection (odds ratio, 3.89; 95% confidence interval, 1.15–13.21; P= 0.029); snare size was not significantly associated with CRR (P= 0.519).
Conclusions
CSP using either a 10-mm or a 15-mm snare for 4–10 mm non-pedunculated colorectal polyps showed no significant difference in complete resection or safety outcomes within this size range. (Clinical Research Information Service [CRIS], KCT0005031)

1,231 View
29 Download

IBD

Knowledge and acceptability of the Lémann Index as a tool to measure disease progression and bowel damage in Crohn’s disease: results from an international survey: Charlotte Wong, Johan Burisch, Ryan C Ungaro, Anthony Buisson, Jérôme Lambert, Jean-Frédéric Colombel, Joana Torres, Naila Arebi; Intest Res 2025;23(4):512-523. Published online October 28, 2025; DOI: https://doi.org/10.5217/ir.2024.00183

Abstract PDF Supplementary Material PubReader ePub: Background/Aims
Crohn’s disease (CD) progresses to structural bowel damage (SBD). The Lémann Index (LI) captures stricture extent/severity, penetrating disease and surgery as a SBD score, and is earmarked for future CD modification trials. Understanding knowledge gaps and perceived barriers is critical to wider adoption.
Methods
A multinational, cross-sectional study was distributed through a survey link (REDCap, Research Electronic Data Capture) to gastrointestinal professional societies with snowball sampling using 23 questionnaire items in 5 sections to determine SBD and LI knowledge, and LI acceptability. Factors associated with acceptability and perception were evaluated.
Results
Of the 107 respondents, 49 (45.8%) were female; 87 (81.3%) were from Europe. Most were inflammatory bowel disease specialists (n = 80, 74.8%) or general gastroenterologists (n = 22, 20.6%), managing > 40 CD patients per month (n = 35, 32.7%). A total of 98 (91.6%) knew about SBD; “very important” rating for clinical trials and clinical practice was 56.1% and 41.4%, respectively. A 39.3% describe LI scoring as “very difficult” or “difficult”; 33.6% reported “significant” or “a lot” of effort. Acceptability (composite scores of > 36) were significantly associated with respondents who had received LI training (P<0.001). Automated methods, intestinal ultrasound and evidence of benefit would encourage LI use in clinical trials, while additional time and automated methods would promote use in clinical practice. The top 3 perceived adoption barriers were: lack of time (60.7%), limited automated methods (47.7%) and need for dedicated radiologists (38.3%).
Conclusions
Most respondents had baseline knowledge of SBD. The LI was perceived as important for advancing future CD research and care. More training and automation will facilitate LI adoption.

1,573 View
25 Download

Review

Endoscopy

Balancing safety and effectiveness in colonoscopy for older adults: a narrative review: Min-Jae Kim, Yuna Kim, Jie-Hyun Kim, Young Hoon Youn, Jaeyoung Chun; Intest Res 2025;23(4):443-454. Published online October 2, 2025; DOI: https://doi.org/10.5217/ir.2025.00092

Abstract PDF PubReader ePub: Colonoscopy is becoming more widely used in older adults for screening and diagnostic evaluation of colorectal cancer. While advanced age itself is not a contraindication, elderly patients often present unique challenges, including frailty, comorbidities and polypharmacy, which increase the risk of complications during the procedure. Rather than chronological age alone, frailty is important in risk assessment and clinical decision-making before performing a colonoscopy. This review summarizes recent evidence, particularly from large cohort studies and clinical guidelines, to provide a balanced evaluation of the advantages and disadvantages of performing colonoscopies on older adults. Ultimately, we emphasize the importance of judicious patient selection, customized bowel preparation and tailored sedation management to optimize the safety and effectiveness of colonoscopy in this vulnerable group.

3,428 View
101 Download

Original Articles

IBD

Effects of COVID-19 vaccines on patient-reported outcomes in patients with inflammatory bowel disease: a multicenter survey study in Korea: Jung Hyun Ji, Seung Hwan Shin, Yong Eun Park, Jihye Park, Jae Jun Park, Jae Hee Cheon, Tae Il Kim, Sang-Bum Kang, Sang Hyoung Park, Soo Jung Park, IBD Research Group of the Korean Association for the Study of Intestinal Diseases (KASID); Intest Res 2024;22(3):336-350. Published online March 26, 2024; DOI: https://doi.org/10.5217/ir.2023.00077

Abstract PDF PubReader ePub

Background/Aims
The impact of vaccination on inflammatory bowel disease (IBD) patients is still unknown, and no studies have assessed the changes in patient-reported outcomes (PROs) after vaccination in patients with IBD. Therefore, in this study, we investigated the impact of vaccines on the PROs of patients with IBD.
Methods
We conducted a questionnaire survey of patients with IBD who visited outpatient clinics at 4 specialized IBD clinics of referral university hospitals from April 2022 to June 2022. A total of 309 IBD patients were included in the study. Patient information was collected from a questionnaire and their medical records, including laboratory findings, were reviewed retrospectively. Risk factors associated with an increase in PROs after COVID-19 vaccination were analyzed using logistic regression analyses. In addition, we assessed whether there were differences in variables by vaccine order using the linear mixed model.
Results
In multivariate analysis, young age ( < 40 years) and ulcerative colitis (UC) were found to be independent risk factors for aggravation of PROs in patients with IBD. In all patients, platelet count significantly increased with continued vaccination in multiple pairwise comparisons. In UC patients, PROs such as the short health scale, UC-abdominal signs and symptoms, and UC-bowel signs and symptoms were aggravated significantly with continued vaccination. There was no significant increase in the variables of patients with Crohn’s disease.
Conclusions
Therefore, there may be a need to counsel patients with IBD younger than 40 years of age, and patients with UC before they receive COVID-19 vaccinations.

Citations

Citations to this article as recorded by

Bowel Urgency in Crohn's Disease: Bridging the Gap Between Patients and Healthcare Providers
Marla Dubinsky, Alison Potts Bleakman, Stephan Vavricka, Simon Travis, Vipul Jairath, Remo Panaccione, María Chaparro, Bénédicte Caron, Deborah A. Fisher, Richard Moses, Aisha Vadhariya, Alissa Walsh
American Journal of Gastroenterology.2025;[Epub] CrossRef

10,779 View
222 Download
1 Crossref

Infection

Comparative outcomes of acute colonic diverticulitis in immunocompromised versus immunocompetent patients: a systematic review and meta-analysis: Jae Gon Lee, Yong Eun Park, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Shin Hee Lee, Myung-Won You, Seong-Eun Kim; Intest Res 2023;21(4):481-492. Published online May 31, 2023; DOI: https://doi.org/10.5217/ir.2023.00005

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Immunocompromised patients with acute colonic diverticulitis are at high risk for complications and failure of non-surgical treatment. However, evidence on the comparative outcomes of immunocompromised and immunocompetent patients with diverticulitis is lacking. This systematic review and meta-analysis investigated the outcomes of medical treatment in immunocompromised and immunocompetent patients with diverticulitis.
Methods
A comprehensive literature search was conducted in PubMed, Embase, and the Cochrane Library. Studies comparing the clinical outcomes of immunocompromised and immunocompetent patients with diverticulitis were included.
Results
A total of 10 studies with 1,946,461 subjects were included in the quantitative synthesis. The risk of emergency surgery and postoperative mortality after emergency surgery was significantly higher in immunocompromised patients than in immunocompetent patients with diverticulitis (risk ratio [RR], 1.76; 95% confidence interval [CI], 1.31–2.38 and RR, 3.05; 95% CI, 1.70–5.45, respectively). Overall risk of complications associated with diverticulitis was non-significantly higher in immunocompromised than in immunocompetent patients (RR, 1.24; 95% CI, 0.95–1.63). Overall mortality irrespective of surgery was significantly higher in immunocompromised than in immunocompetent patients with diverticulitis (RR, 3.65; 95% CI, 1.73–7.69). By contrast, postoperative mortality after elective surgery was not significantly different between immunocompromised and immunocompetent patients with diverticulitis. In subgroup analysis, the risk of emergency surgery and recurrence was significantly higher in immunocompromised patients with complicated diverticulitis, whereas no significant difference was shown in mild disease.
Conclusions
Immunocompromised patients with diverticulitis should be given the best medical treatment with multidisciplinary approach because they had increased risks of surgery, postoperative morbidity, and mortality than immunocompetent patients.

Citations

Citations to this article as recorded by

Comparison of Outcomes Following Surgery for Diverticulitis Among Immunocompetent and Immunosuppressed Patients
Usama Waqar, Christina Gozza, Courtney L. Devin, Terrah J. Paul Olson, Seth A. Rosen
The American Surgeon™.2025; 91(7): 1093. CrossRef
Global guidelines on diverticular disease of the colon: the Fiesole Consensus report
Antonio Tursi, Giovanni Brandimarte, Francesco Di Mario, Wenjie Ma, Juozas Kupcinskas, Jaroslaw Regula, Giovanni Maconi, Peter Malfertheiner, Giovanni Barbara, Neil Stollman, Savvas Papagrigoriadis, Thomas Golda, Antonio Amato, Mauro Bafutto, Gabrio Basso
Gut.2025; : gutjnl-2025-336902. CrossRef
Does type II diabetes mellitus increase the morbidity of patients with diverticulitis?
Marei H. Alshandeer, Walid M. Abd El Maksoud, Khaled S. Abbas, Fahad S. Al Amri, Maha A. Alghamdi, Hassan A. Alzahrani, Abdullah Dalboh, Mohammed A. Bawahab, Aisha J. Asiri, Yahia Assiri
Medicine.2024; 103(46): e40567. CrossRef
Not all acute colonic diverticulitis follows the same course: a potential risk for immunocompromised individuals
Yehyun Park
Intestinal Research.2023; 21(4): 415. CrossRef

7,283 View
376 Download
4 Web of Science
4 Crossref

IBD

Inflammatory bowel disease (IBD)-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD: Arshdeep Singh, Yogesh Kumar Gupta, Ashvin Singh Dhaliwal, Bhavjeet Kaur Kahlon, Vasu Bansal, Ramit Mahajan, Varun Mehta, Dharmatma Singh, Ramandeep Kaur, Namita Bansal, Vandana Midha, Ajit Sood; Intest Res 2023;21(3):375-384. Published online October 18, 2022; DOI: https://doi.org/10.5217/ir.2022.00037

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
The inflammatory bowel disease (IBD)-disk is a validated, visual, 10-item, self-administered questionnaire used to evaluate IBD-related disability. The present study aimed to evaluate IBD-disk in assessment of IBD daily life burden and its relation with disease activity. Methods: A cross-sectional study was conducted between June 2021 and December 2021. Patients with IBD were asked to complete the IBD-disk and a visual analogue scale of IBD daily-life burden (scored from 0–10, score >5 indicative of high burden). The internal consistency of IBD-disk, correlation with IBD daily life burden and disease activity (assessed by partial Mayo score and Harvey Bradshaw Index in patients with ulcerative colitis [UC] and Crohn’s disease [CD], respectively) and diagnostic performance of IBD-disk to detect high burden were analyzed. Results: Out of the 546 patients (mean age 40.33±13.74 years, 282 [51.6%] males) who completed the IBD-disk, 464 (84.98%) had UC and the remaining (n=82, 15.02%) had CD. A total of 311 patients (291 UC and 20 CD; 56.95%) had active disease. The mean IBD-disk total score and IBD daily life burden were 18.39±15.23 and 2.45±2.02, respectively. The IBD-disk total score correlated strongly with the IBD daily life burden (ρ=0.94, P<0.001), moderately with partial Mayo score (ρ=0.50) and weakly with Harvey Bradshaw Index (ρ=0.34). The IBD-disk total score >30 predicted high IBD daily-life burden. Conclusions: The IBD-disk accurately predicts the daily life burden and parallels disease activity in patients with IBD and can be applied in clinical practice. (Intest Res, Published online)

Citations

Citations to this article as recorded by

Prospective Bi-Centric Real-World Outcomes of Upadacitinib in Biologic-Experienced Patients with Crohn’s Disease
Janina Lüke, Clara Zippel, Phil-Robin Tepasse, Frank Lenze, Markus Strauss, Arne Bokemeyer, Joost Buskermolen, Tina Schomacher, Julia Fischer, Jonel Trebicka, Richard Vollenberg
Diseases.2026; 14(2): 54. CrossRef
Advances in Crohn's Disease: A Comprehensive Review of Pathophysiology, Diagnosis, and Emerging Therapeutics
Yoon‐Kyo An, Robert Gilmore, Graham Radford‐Smith, Jakob Begun
JGH Open.2026;[Epub] CrossRef
Is IBD Disk a Reliable Tool to Detect Depression in IBD Patients? A Comparison with Becks’ Depression Inventory
Teodora Spataru, Ana Stemate, Marina Cozma, Alexandru Fleschiu, Remus Popescu, Lucian Negreanu
Gastrointestinal Disorders.2025; 7(1): 23. CrossRef
Development of a technology-enhanced patient-reported outcome evaluation system for inflammatory bowel disease: A multidimensional approach to assessing survival quality
Qian Jiang, Ling Du
Technology and Health Care.2025;[Epub] CrossRef
IBD-PODCAST Spain: A Close Look at Current Daily Clinical Practice in IBD Management
P. Vega, J. M. Huguet, E. Gómez, S. Rubio, P. Suarez, M. I. Vera, J. M. Paredes, A. Hernández-Camba, R. Plaza, M. Mañosa, R. Pajares, B. Sicilia, L. Madero, S. Kolterer, C. Leitner, T. Heatta-Speicher, N. Michelena, R. Santos de Lamadrid, A. Dignass, F. G
Digestive Diseases and Sciences.2024; 69(3): 749. CrossRef
Proportion of inflammatory bowel diseases patients with suboptimal disease control in daily clinical practice—Real‐world evidence from the inflammatory bowel diseases‐podcast study
Ferdinando D’Amico, Fernando Gomollón, Giorgos Bamias, Fernando Magro, Laura Targownik, Claudia Leitner, Tobias Heatta‐Speicher, Naiara Michelena, Stefanie Kolterer, Jennifer Lapthorn, Laura Kauffman, Axel Dignass
United European Gastroenterology Journal.2024; 12(6): 705. CrossRef
A Cross-Sectional Evaluation of Disability in Inflammatory Bowel Disease Using IBD Disk in a Tertiary Center from Romania
Oana-Maria Muru, Corina Silvia Pop, Petruța Violeta Filip, Nicoleta Tiucă, Laura Sorina Diaconu
Journal of Clinical Medicine.2024; 13(23): 7168. CrossRef
Perceptions and Responses to Diseases among Patients with Inflammatory Bowel Disease: Text Mining Analysis of Posts on a Japanese Patient Community Website
Eujin Lee, Hiroaki Tsuchiya, Hajime Iida, Katsumasa Nagano, Yoko Murata, Atsuo Maemoto
Inflammatory Intestinal Diseases.2024; 9(1): 283. CrossRef

8,013 View
469 Download
6 Web of Science
8 Crossref

IBD

Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study: Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Kim, Do Hyun Kim, Dennis Teng, Jong-Hwa Kim, Wonyong Kim, Chang Hwan Choi, on behalf of the IBD Research Group of the Korean Association for the Study of Intestinal Diseases; Intest Res 2022;20(3):350-360. Published online July 23, 2021; DOI: https://doi.org/10.5217/ir.2021.00049

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
This study assessed the efficacy and safety of adalimumab (ADA) and explored predictors of response in Korean patients with ulcerative colitis (UC).
Methods
A prospective, observational, multicenter study was conducted over 56 weeks in adult patients with moderately to severely active UC who received ADA. Clinical response, remission, and mucosal healing were assessed using the Mayo score.
Results
A total of 146 patients were enrolled from 17 academic hospitals. Clinical response rates were 52.1% and 37.7% and clinical remission rates were 24.0% and 22.0% at weeks 8 and 56, respectively. Mucosal healing rates were 39.0% and 30.1% at weeks 8 and 56, respectively. Prior use of anti-tumor necrosis factor-α (anti-TNF-α) did not affect clinical and endoscopic responses. The ADA drug level was significantly higher in patients with better outcomes at week 8 (P<0.05). In patients with lower endoscopic activity, higher body mass index, and higher serum albumin levels at baseline, the clinical response rate was higher at week 8. In patients with lower Mayo scores and C-reactive protein levels, clinical responses, and mucosal healing at week 8, the clinical response rate was higher at week 56. Serious adverse drug reactions were identified in 2.8% of patients.
Conclusions
ADA is effective and safe for induction and maintenance in Korean patients with UC, regardless of prior anti-TNF-α therapy. The ADA drug level is associated with the efficacy of induction therapy. Patients with better short-term outcomes were predictive of those with an improved long-term response.

Citations

Citations to this article as recorded by

Impact of 5‐ASA discontinuation in children with ulcerative colitis on biologic therapy: A propensity score‐matched study
Giulia D'Arcangelo, Luca Scarallo, Giulia Mancuso, Mara Corpino, Claudio Romano, Lorenzo Norsa, Serena Arrigo, Matteo Bramuzzo, Maria Teresa Fioretti, Giovanna Zuin, Maria Teresa Illiceto, Paolo Lionetti, Marina Aloi
Journal of Pediatric Gastroenterology and Nutrition.2026;[Epub] CrossRef
Development and Validation of a Clinical Decision Support Tool to Predict Disease Progression in Crohn’s Disease Treated with Ustekinumab
Lingya Yao, Yushu Cao, Chenhao Bai, Rongbei Liu, Wenjing Yang, Kang Chao, Zhaopeng Huang, Yun Qiu, Xiang Gao, Minhu Chen, Qian Cao
Journal of Clinical Medicine.2025; 14(22): 7919. CrossRef
Prospective Observational Evaluation of the Time-Dependency of Adalimumab Immunogenicity and Drug Concentration in Ulcerative Colitis Patients: the POETIC II Study
Sivan Harnik, Chaya M Abitbol, Ola Haj Natour, Miri Yavzori, Ella Fudim, Orit Picard, Timna Naftali, Efrat Broide, Ayal Hirsch, Limor Selinger, Eyal Shachar, Doron Yablecovitch, Ahmad Albshesh, Daniel Coscas, Uri Kopylov, Rami Eliakim, Shomron Ben-Horin,
Journal of Crohn's and Colitis.2024; 18(3): 341. CrossRef
Rapidly achieving clinical remission in ulcerative colitis indicates better endoscopic and histological outcomes
Rirong Chen, Yizhe Tie, Yongle Huang, Xi Zhang, Zhirong Zeng, Minhu Chen, Li Li, Shenghong Zhang
United European Gastroenterology Journal.2024; 12(4): 459. CrossRef
Effectiveness of adalimumab in severe ulcerative colitis: A systematic review and a meta‐analysis
Saleh Azadbakht, Masomeh Seighali, Salehe Azadbakht, Morteza Azadbakht
Health Science Reports.2024;[Epub] CrossRef
Dynamic changes in the gut microbiota composition during adalimumab therapy in patients with ulcerative colitis: implications for treatment response prediction and therapeutic targets
Han Na Oh, Seung Yong Shin, Jong-Hwa Kim, Jihye Baek, Hyo Jong Kim, Kang-Moon Lee, Soo Jung Park, Seok-Young Kim, Hyung-Kyoon Choi, Wonyong Kim, Woo Jun Sul, Chang Hwan Choi
Gut Pathogens.2024;[Epub] CrossRef
Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
Peter M. Irving, Peter Hur, Raju Gautam, Xiang Guo, Severine Vermeire
Journal of Managed Care & Specialty Pharmacy.2024; 30(9): 1026. CrossRef
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Soo-Young Na, Chang Hwan Choi, Eun Mi Song, Ki Bae Bang, Sang Hyoung Park, Eun Soo Kim, Jae Jun Park, Bora Keum, Chang Kyun Lee, Bo-In Lee, Seung-Bum Ryoo, Seong-Joon Koh, Miyoung Choi, Joo Sung Kim
Intestinal Research.2023; 21(1): 61. CrossRef
Changes in fecal metabolic and lipidomic features by anti-TNF treatment and prediction of clinical remission in patients with ulcerative colitis
Seok-Young Kim, Seung Yong Shin, Soo Jung Park, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Reviewing not Homer’s Iliad, but “Kai Bao Ben Cao”: indigo dye—the past, present, and future
Yusuke Yoshimatsu, Tomohisa Sujino, Takanori Kanai
Intestinal Research.2023; 21(2): 174. CrossRef
Precision medicine and drug optimization in adult inflammatory bowel disease patients
Sophie Vieujean, Edouard Louis
Therapeutic Advances in Gastroenterology.2023;[Epub] CrossRef
Real-world effectiveness and safety of adalimumab in Korean patients with intestinal Behcet’s disease: a Korean Association for the Study of Intestinal Diseases (KASID) multicenter study
Seung Bum Lee, Hee Seung Hong, Chang Kyun Lee, Bo-In Lee, Sol Kim, Seong-Joon Koh, Hosun Yu, Jung-Bin Park, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Sang Hyoung Park
The Korean Journal of Internal Medicine.2023; 38(5): 661. CrossRef
Advancements in the Management of Moderate-to-Severe Ulcerative Colitis: A Revised 2023 Korean Treatment Guidelines
Soo-Young Na
The Korean Journal of Medicine.2023; 98(5): 223. CrossRef
Prediction of Clinical Remission with Adalimumab Therapy in Patients with Ulcerative Colitis by Fourier Transform–Infrared Spectroscopy Coupled with Machine Learning Algorithms
Seok-Young Kim, Seung Yong Shin, Maham Saeed, Ji Eun Ryu, Jung-Seop Kim, Junyoung Ahn, Youngmi Jung, Jung Min Moon, Chang Hwan Choi, Hyung-Kyoon Choi
Metabolites.2023; 14(1): 2. CrossRef
Association of C-reactive Protein and Partial Mayo Score With Response to Tofacitinib Induction Therapy: Results From the Ulcerative Colitis Clinical Program
Marla C Dubinsky, Fernando Magro, Flavio Steinwurz, David P Hudesman, Jami A Kinnucan, Ryan C Ungaro, Markus F Neurath, Nicole Kulisek, Jerome Paulissen, Chinyu Su, Dario Ponce de Leon, Miguel Regueiro
Inflammatory Bowel Diseases.2022;[Epub] CrossRef
Effectiveness and Safety of Golimumab in Patients with Ulcerative Colitis: A Multicenter, Prospective, Postmarketing Surveillance Study
Jongwook Yu, Soo Jung Park, Hyung Wook Kim, Yun Jeong Lim, Jihye Park, Jae Myung Cha, Byong Duk Ye, Tae Oh Kim, Hyun-Soo Kim, Hyun Seok Lee, Su Young Jung, Youngdoe Kim, Chang Hwan Choi
Gut and Liver.2022; 16(5): 764. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef

13,340 View
678 Download
19 Web of Science
17 Crossref

IBD

A nationwide analysis on the influence of obesity in inflammatory bowel disease hospitalizations: Dushyant Singh Dahiya, Asim Kichloo, Farah Wani, Jagmeet Singh, Dhanshree Solanki, Hafeez Shaka; Intest Res 2022;20(3):342-349. Published online May 21, 2021; DOI: https://doi.org/10.5217/ir.2021.00046

Abstract PDF PubReader ePub

Background/Aims
Proinflammatory cytokines released from adipocytes can influence the development, progression, and treatment of inflammatory bowel disease (IBD), and may be associated with worse clinical outcomes.
Methods
For 2016–2018, we analyzed data from the Nationwide Inpatient Sample to identify adult (≥18 years) hospitalizations with a primary discharge diagnosis of IBD. The study sample was divided based on the presence or absence of obesity. The primary outcomes included inpatient mortality, while the secondary outcomes consisted of system-based complications and disease implications on the United States healthcare system.
Results
We identified 282,005 hospitalizations of IBD from 2016 to 2018. Of these hospitalizations, 26,465 (9.4%) had a secondary diagnosis of obesity while 255,540 (90.6%) served as controls. IBD hospitalizations with obesity had a higher mean age (47.9 years vs. 45.2 years, P<0.001), middle age (range, 40–65 years) predominance (37.7% vs. 28.9%, P<0.001), female predominance (64.1% vs. 52.5%, P<0.001) and higher proportion of patients with comorbidities compared to the non-obese cohort. White predominance was observed in both subgroups. No difference in the odds of inpatient mortality was noted between the 2 subgroups; however, IBD hospitalizations with obesity had higher mean total hospital charge ($50,126 vs. $45,001, P<0.001), longer length of stay (5.5 days vs. 4.9 days, P<0.001) and higher proportion of complications compared to the non-obese cohort.
Conclusions
Obese IBD hospitalizations had higher length of stay, total hospital charge, and complications compared to the non-obese cohort.

Citations

Citations to this article as recorded by

Obesity and Chronic Inflammation: Implications for Rheumatoid Arthritis, Spondyloarthritis, and Ulcerative Colitis
Ada Corrado, Ilaria Guadagni, Giovanna Picarelli, Angela Variola
Immunity, Inflammation and Disease.2025;[Epub] CrossRef
Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences
Elena Grueso Navarro, Alfredo J. Lucendo
Expert Review of Clinical Immunology.2025; 21(7): 875. CrossRef
Obesity-Mediated Inflammation and Its Influence on Inflammatory Bowel Disease: Pathophysiology, Clinical Impact, and Therapeutic Implications
Diego Casas-Deza, Santiago García-López, Vanesa Bernal-Monterde, Cristina Polo-Cuadro, Carmen Yagüe-Caballero, José M. Arbones-Mainar
Biomolecules.2025; 15(8): 1185. CrossRef
Efficacy of GLP-1 receptor agonists on obesity and metabolic profile in patients with inflammatory bowel disease: a systematic review and meta-analysis
Fatemeh Ojaghi Shirmard, Seyed Morteza Pourfaraji, Mahyaar Omouri-Kharashtomi, Arash Amani
BMC Gastroenterology.2025;[Epub] CrossRef
Can GLP-1 agonists be used safely in inflammatory bowel disease? A meta-analysis
Noppachai Siranart, Pannathorn Nakaphan, Patavee Pajareya, Khamik Laohasurayotin
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis
Ahmed B Bayoumy, Lindsay M Clarke, Parakkal Deepak, Aakash Desai, Priya Sehgal, uri Gorelik, Haggai Bar-Yoseph, Marie Villumsen, Chris J J Mulder, Dirk J Stenvers, Maarten E Tushuizen, Nanne K H de Boer
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
Recomendaciones sobre el manejo de la obesidad grave en pacientes con enfermedad inflamatoria intestinal del Grupo Español de Trabajo en Enfermedad Inflamatoria Intestinal (GETECCU), Sociedad Española de Obesidad (SEEDO), Asociación Española de Cirugía (A
Eugeni Domènech, Andreea Ciudin, José María Balibrea, Eduard Espinet-Coll, Fiorella Cañete, Lilliam Flores, Manuel Ferrer-Márquez, Román Turró, Alejandro Hernández-Camba, Yamile Zabana, Ana Gutiérrez, José María Balibrea, Manuel Barreiro-de Acosta, Javier
Gastroenterología y Hepatología.2024; 47(8): 906. CrossRef
The Rising Epidemic of Obesity in Patients with Inflammatory Bowel Disease
Jellyana Peraza, Erin Abbott, Mark Shneyderman, Asher Kornbluth, Maitreyi Raman, Stephanie Gold
Current Treatment Options in Gastroenterology.2024; 22(3): 134. CrossRef
Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn’s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish
Eugeni Domènech, Andreea Ciudin, José María Balibrea, Eduard Espinet-Coll, Fiorella Cañete, Lilliam Flores, Manuel Ferrer-Márquez, Román Turró, Alejandro Hernández-Camba, Yamile Zabana, Ana Gutiérrez, José María Balibrea, Manuel Barreiro-de Acosta, Javier
Gastroenterología y Hepatología (English Edition).2024; 47(8): 906. CrossRef
Body Mass Index Profile of Adult Patients with Inflammatory Bowel Disease in a Multicenter Study in Northeastern Brazil
Jones Lima, Carlos Brito, Lívia Celani, Marcelo Vicente Araújo, Maurilio Lucena, Graciana Vasconcelos, Gustavo Lima, Fernando Nóbrega, George Diniz, Norma Lucena-Silva, Regiane Maio, Valéria Martinelli
Clinical and Experimental Gastroenterology.2023; Volume 16: 213. CrossRef
Clinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study
Seung Yong Shin, Soo Jung Park, Young Kim, Jong Pil Im, Hyo Jong Kim, Kang-Moon Lee, Ji Won Kim, Sung-Ae Jung, Jun Lee, Sang-Bum Kang, Sung Jae Shin, Eun Sun Kim, You Sun Kim, Tae Oh Kim, Hyun-Soo Kim, Dong Il Park, Hyung Kil Kim, Eun Soo Kim, Young-Ho Ki
Intestinal Research.2022; 20(3): 350. CrossRef

8,163 View
514 Download
10 Web of Science
11 Crossref

Review

IBD

An integrative review of physical activity in adults with inflammatory bowel disease: Suja P Davis, Patricia B. Crane, Linda P. Bolin, Lee Ann Johnson; Intest Res 2022;20(1):43-52. Published online January 22, 2021; DOI: https://doi.org/10.5217/ir.2020.00049

Abstract PDF Supplementary Material PubReader ePub

Adults with inflammatory bowel disease (IBD) search for self-management strategies to manage their symptoms and improve their quality of life (QOL). Physical activity (PA) is one of the self-management strategies widely adopted by adults with IBD. This integrative review aimed to synthesize the evidence on health outcomes of PA in adults with IBD as well as to identify the barriers to engaging in PA. Using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA), published literature was searched to identify the articles that addressed PA in adults with IBD. Twenty-eight articles met the inclusion criteria. Many of the reviewed studies used the terms of PA and exercise interchangeably. Walking was the most common PA reported in the studies. The findings from the majority of the reviewed studies supported the benefits of moderate-intensity exercise/PA among adults with IBD. The reviewed studies noted the following positive health outcomes of PA: improvement in QOL, mental health, sleep quality, gastrointestinal symptoms, fatigue and cardiorespiratory fitness. More importantly, participation in PA reduced the risk for development of IBD and the risk for future active disease. The findings from the reviewed studies highlighted the following barriers to engage in PA: fatigue, joint pain, abdominal pain, bowel urgency, active disease and depression.

Citations

Citations to this article as recorded by

Advances in the Application of Digital Health Technologies in the Management of Patients With Inflammatory Bowel Disease
Jing Yuan, Dandan Zhao
The American Surgeon™.2026; 92(5): 1546. CrossRef
Association between physical activity with disease activity and functional disability in patients with inflammatory bowel disease
Maud Gendard, Philippe Seksik, Carmen Stefanescu, Antoine Meyer, Maria Nachury, Stéphane Nancey, Guillaume Savoye, Matthieu Allez, David Laharie, Mélanie Serrero, Denis Franchimont, Nicolas Mathieu, Mathurin Fumery, Lucine Vuitton, Stéphane Nahon, Cyriell
Digestive and Liver Disease.2026; 58(4): 479. CrossRef
Objective assessment of physical activity using wearable devices in patients with mild-to-moderate Crohn’s disease
Briana Toews, Maitreyi Raman, Reed Ferber, Cathy Lu, Raylene A Reimer
Journal of the Canadian Association of Gastroenterology.2026;[Epub] CrossRef
Trends and Factors Related to Quality of Life in Patients with Inflammatory Bowel Disease
Sihyun Kim, Yu Kyung Jun, Yonghoon Choi, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyuk Yoon
Gut and Liver.2025; 19(2): 236. CrossRef
Management of Fatigue in Inflammatory Bowel Disease: A Narrative Review
Dan-Dan Wang, Shi-Guang Ren, Rui Hu, Hui-Lan Zhai, Fen Xie, Lu Jiang, Wen-Lei Huang, Xue-Qin Li
International Journal of General Medicine.2025; Volume 18: 1403. CrossRef
Validity and Reliability of the Self‐Care of Chronic Illness Inventory in Patients Living With Inflammatory Bowel Disease
Daniele Napolitano, Valentina Biagioli, Davide Bartoli, Silvia Cilluffo, Piergiorgio Martella, Alessandro Monaci, Ercole Vellone, Antonello Cocchieri
Journal of Clinical Nursing.2025; 34(11): 4642. CrossRef
A review of the link between psychological stress and inflammatory bowel disease exacerbation
Annelise Klettner, Shanhong Luo, Laura D. Coyle, Nathan Liu
Academia Mental Health and Well-Being.2025;[Epub] CrossRef
Effectiveness of an app-based walking program for obese patients with inflammatory bowel disease in Korea: a single-blind parallel-group randomized clinical trial
Young Jin Lee, Eun Ja Kwon, Da-In Park, Sang Hyoung Park, Sung Wook Hwang, Byong Duk Ye
BMC Gastroenterology.2025;[Epub] CrossRef
A Population-Based Assessment of Physical Activity and Exercise in Persons With IBD
Sydney Chochinov, Casandra Dolovich, Gia Ly, Adebanke Oketola, Samuel Narvey, Maitreyi Raman, Sandra Webber, Charles N. Bernstein
Journal of Clinical Gastroenterology.2025;[Epub] CrossRef
Patterns and Correlates of Sedentary Behavior and Physical Activity in Individuals With Crohn’s Disease: A Cross-Sectional Study
Jason J Wilson, Barry Lynch, Nathan Graham, Conor M McClean, Mark A Tully
Crohn's & Colitis 360.2025;[Epub] CrossRef
Physical activity among people with an inflammatory bowel disease: a systematic review of antecedents
Cameron Trim, Sharan Srinivasa Gopalan, Ryan Rhodes
Psychology, Health & Medicine.2025; : 1. CrossRef
Behaviour Change Considerations to Promote Physical Activity Participation among Individuals with Quiescent Inflammatory Bowel Disease: Barriers and Facilitators
Banke Oketola, Sandra Webber, Harminder Singh, Maia Kredentser, Kristin Reynolds, Gayle Restall
Advances in Rehabilitation Science and Practice.2025;[Epub] CrossRef
Qualitative Exploration of Barriers and Facilitators to Physical Activity and Exercise in Children and Adolescents With Crohn’s—Perspectives of Young People, Caregivers, and Clinicians
Zoe L. Saynor, Nadeem A. Afzal, Christopher Roberts, Kelly A. Mackintosh, Danielle Lambrick, James Faulkner, Will Freer, Elena Kurteva, Thierry Middleton, Heather Hunter
Pediatric Exercise Science.2025; : 1. CrossRef
Physical Activity and Education in the Care of IBD: The Role of the Physiotherapist—A Narrative Review
Zita Kovács, Péter Bacsur, Blanka Bernadett Kasza, Tamás Molnár, Andrea Domján
Journal of Clinical Medicine.2025; 14(23): 8602. CrossRef
Abdominally targeted physical exercises as a therapeutic intervention for inflammatory bowel diseases
Lael Werner, Rony Izhar, Morine Fibelman, Izislav Shapiro, Andrei Siderskyi, Yuri Ostrinski, Haim Leibovitzh, Nathaniel Aviv Cohen, Ayal Hirsch, Yulia Ron, Naomi Fliss Isakov, Nitsan Maharshak
Journal of Science and Medicine in Sport.2025;[Epub] CrossRef
Physical activity, sedentary behavior and risk of inflammatory bowel disease: a prospective cohort study in the UK Biobank
Siqin Xia, Jie Zhang, Zixing Zhang, Xiang Wang, Dongqing Ye, Xinyu Fang
BMC Public Health.2025;[Epub] CrossRef
The complex relationship between physical activity and fatigue with socioeconomic status, and mental health factors in individuals with inflammatory bowel disease
Casandra Dolovich, Sydney Chochinov, Gia Ly, Banke Oketola, Sam Narvey, Sydney Larance, Maitreiy Raman, Sandra C Webber, Charles N Bernstein
Journal of Crohn's and Colitis.2025;[Epub] CrossRef
Physical Activity Is Inversely Associated with Clinical Exacerbation in Patients with Crohn’s Disease in Remission: A Prospective Cohort Study
Chen Sarbagili-Shabat, Shira Zelber-Sagi, Naomi Fliss Isakov, Ayal Hirsch, Yulia Ron, Laura Sol Grinshpan, Nathaniel Aviv Cohen, Haim Leibovitzh, Tamar Thurm, Nitsan Maharshak
Digestive Diseases.2025; 44(1): 63. CrossRef
Physical exercises as an effective adjuvant therapy of IBD in remission (review)
S. V. Kostyukevich, I. G. Bakulin
Koloproktologia.2024; 23(1): 152. CrossRef
Bridging the gap: Unveiling the crisis of physical inactivity in inflammatory bowel diseases
Remus Stafie, Ana-Maria Singeap, Adrian Rotaru, Carol Stanciu, Anca Trifan
World Journal of Gastroenterology.2024; 30(10): 1261. CrossRef
Progress in research of exercise intervention in inflammatory bowel disease
Shao-Peng Sun, Jia-Jia Chen, Ming-Xu Zheng, Yi-Hong Fan, Bin Lv
World Chinese Journal of Digestology.2024; 32(5): 339. CrossRef
Unresolved conundrum of the role of physical activity in irritable bowel disease: What next?
Nilakantan Ananthakrishnan
World Journal of Gastroenterology.2024; 30(21): 2744. CrossRef
Metabolic and lifestyle factors accelerate disease onset and alter gut microbiome in inflammatory non-communicable diseases
Nathalie Rohmann, Theresa Geese, Samantha Nestel, Kristina Schlicht, Corinna Geisler, Kathrin Türk, Fynn Brix, Julia Jensen-Kroll, Tobias Demetrowitsch, Corinna Bang, Andre Franke, Wolfgang Lieb, Dominik M. Schulte, Karin Schwarz, Anne-Kathrin Ruß, Arunab
BMC Medicine.2024;[Epub] CrossRef
Too Many Couch Potatoes Among Middle-Aged Inflammatory Bowel Disease Patients: Findings from the “BE-FIT-IBD-2” Study
Antonietta Gerarda Gravina, Raffaele Pellegrino, Giovanna Palladino, Annalisa Zanini, Alessandro Federico, Fabiana Zingone
Gastroenterology Insights.2024; 15(4): 963. CrossRef
Activité physique et MICI
Xavier Hébuterne
Nutrition Clinique et Métabolisme.2024; 38(4): 217. CrossRef
Chronic Abdominal Pain in Patients with Inflammatory Bowel Disease in Remission: A Continuing Challenge for Clinicians
Natasha Klemm, Sarvee Moosavi
Digestive Diseases and Sciences.2024; 69(12): 4336. CrossRef
Mechanisms of Insulin Signaling as a Potential Therapeutic Method in Intestinal Diseases
Sara Jarmakiewicz-Czaja, Aneta Sokal-Dembowska, Katarzyna Ferenc, Rafał Filip
Cells.2024; 13(22): 1879. CrossRef
Adjunct Therapies to Standard Care for IBS and IBD Patients: Digestive Symptoms Improvement and Quality of Life Optimization
Veronique Traynard
Nutrients.2024; 16(22): 3927. CrossRef
Unlocking the Power of Physical Activity in Inflammatory Bowel Disease: A Comprehensive Review
Jiajia Chen, Shaopeng Sun, Andrew S. Day
Gastroenterology Research and Practice.2024;[Epub] CrossRef
The impact of physical exercise on health-related quality of life in inflammatory bowel disease
Ayokunle T Abegunde, Daniela Goyes, Umer Farooq, Amy H Luke, Elizabeth Huggins, Richard S Cooper, Lara R Dugas
Cochrane Database of Systematic Reviews.2023;[Epub] CrossRef
Patients’ perspectives on, experience with and concerns about crohn's disease: insights from Chinese social media
Shaopeng Sun, Yunhong Hu, Heng Li, Jiajia Chen, Yijie Lou, Chunyan Weng, Lixia Chen, Bin Lv
BMC Gastroenterology.2023;[Epub] CrossRef
Fecal Calprotectin in Gastrointestinal Disease
Jennifer Murray, Klaartje B Kok, Ruth M Ayling
Clinical Chemistry.2023; 69(7): 699. CrossRef
Physical activity, quality of diet and bone mineral density in patients with inflammatory bowel disease
Alicja E. Ratajczak‐Pawłowska, Michał Michalak, Aleksandra Szymczak‐Tomczak, Anna Maria Rychter, Agnieszka Zawada, Kinga Skoracka, Agnieszka Dobrowolska, Iwona Krela‐Kaźmierczak
Journal of Human Nutrition and Dietetics.2023; 36(5): 1692. CrossRef
Physical Activity in Pediatric Inflammatory Bowel Disease: A Scoping Review
Lee Hill, Noushin Roofigari, Maria Faraz, Jelena Popov, Michal Moshkovich, Melanie Figueiredo, Emily Hartung, Meryem Talbo, Marie-Laure Lalanne-Mistrih, Mary Sherlock, Mary Zachos, Brian W. Timmons, Joyce Obeid, Nikhil Pai
Pediatric Exercise Science.2023; : 1. CrossRef
Inflammatory bowel diseases patients suffer from significant low levels and barriers to physical activity: The “BE-FIT-IBD” study
Antonietta Gerarda Gravina, Raffaele Pellegrino, Tommaso Durante, Giovanna Palladino, Rossella D’Onofrio, Simone Mammone, Giusi Arboretto, Salvatore Auletta, Giuseppe Imperio, Andrea Ventura, Mario Romeo, Alessandro Federico
World Journal of Gastroenterology.2023; 29(41): 5668. CrossRef
Effects of yoga in inflammatory bowel diseases and on frequent IBD-associated extraintestinal symptoms like fatigue and depression
E. Wilke, W. Reindl, P.A. Thomann, M.P. Ebert, T. Wuestenberg, A.K. Thomann
Complementary Therapies in Clinical Practice.2021; 45: 101465. CrossRef
Physical Activity in Patients With Inflammatory Bowel Disease: A Narrative Review
Maitreyi Raman, Vidya Rajagopalan, Sandeep Kaur, Raylene A Reimer, Christopher Ma, Subrata Ghosh, Jeff Vallance
Inflammatory Bowel Diseases.2021;[Epub] CrossRef

18,740 View
499 Download
34 Web of Science
37 Crossref

Original Articles

IBD

The impact of corticosteroid use on inpatients with inflammatory bowel disease and positive polymerase chain reaction for Clostridium difficile: Huei-Wen Lim, Isaiah P. Schuster, Ramona Rajapakse, Farah Monzur, Sundas Khan, Keith Sultan; Intest Res 2019;17(2):244-252. Published online February 12, 2019; DOI: https://doi.org/10.5217/ir.2018.00101

Abstract PDF PubReader ePub

Background/Aims
Optimal management of inflammatory bowel disease (IBD) with concomitant Clostridium difficile infection (CDI) is controversial, especially when CDI diagnosis is made by polymerase chain reaction (PCR) testing, which may reflect colonization without infection.
Methods
We performed a multicenter review of all inpatients with IBD and PCR diagnosed CDI. Outcomes included length of stay, 30- and 90-day readmission, colectomy during admission and within 3 months, intensive care unit (ICU) admission, CDI relapse and death for patients who received corticosteroid (CS) after CDI diagnosis versus those that did not. Propensity-adjusted regression analysis of outcomes based on CS usage was performed.
Results
We identified 177 IBD patients with CDI, 112 ulcerative colitis and 65 Crohn’s disease. For IBD overall, CS after CDI diagnosis was associated with prolonged hospitalization (5.5 days: 95% confidence interval [CI], 1.5–9.6 days; P=0.008), higher colectomy rate within 3 months (odds ratio [OR], 5.5; 95% CI, 1.1–28.2; P=0.042) and more frequent ICU admissions (OR, 7.8; 95% CI, 1.5–41.6; P=0.017) versus no CS. CS use post-CDI diagnosis in UC patients was associated with prolonged hospitalization (6.2 days: 95% CI, 0.4– 12.0 days; P=0.036) and more frequent ICU admissions (OR, 7.4; 95% CI, 1.1–48.7; P=0.036).
Conclusions
CS use among IBD inpatients with CDI diagnosed by PCR is associated with poorer outcomes and would seem to reinforce the importance of C. difficile toxin assay to help distinguish colonization from infection. This adverse effect appears more prominent among those with UC.

Citations

Citations to this article as recorded by

Clostridioides difficile infection in inflammatory bowel disease: a clinical review
Mengjun Tang, Chunhua Wang, Ying Xia, Jian Tang, Jiao Wang, Liang Shen
Expert Review of Anti-infective Therapy.2024; 22(5): 297. CrossRef
The Current Knowledge on Clostridioides difficile Infection in Patients with Inflammatory Bowel Diseases
Alina Boeriu, Adina Roman, Crina Fofiu, Daniela Dobru
Pathogens.2022; 11(7): 819. CrossRef
Korean Association for the Study of Intestinal Diseases guidance for clinical practice of adult inflammatory bowel disease during the coronavirus disease 2019 pandemic: expert consensus statements
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
Intestinal Research.2022; 20(4): 431. CrossRef
KASID Guidance for Clinical Practice Management of Adult Inflammatory Bowel Disease during the COVID-19 Pandemic: Expert Consensus Statement
Yong Eun Park, Yoo Jin Lee, Ji Young Chang, Hyun Joo Song, Duk Hwan Kim, Young Joo Yang, Byung Chang Kim, Jae Gon Lee, Hee Chan Yang, Miyoung Choi, Seong-Eun Kim, Seung-Jae Myung
The Korean Journal of Gastroenterology.2021; 78(2): 105. CrossRef

10,942 View
176 Download
4 Web of Science
4 Crossref

IBD

Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children’s immunity: Ko Eun Lee, Sung-Ae Jung, Sang Hyoung Park, Chang Mo Moon, So Yeon Shim, Eun Soo Kim, Su Jin Cho, Seong-Eun Kim, Kwang Bum Cho, Suk-Kyun Yang; Intest Res 2019;17(2):237-243. Published online February 8, 2019; DOI: https://doi.org/10.5217/ir.2018.00071

Abstract PDF PubReader ePub

Background/Aims
The onset of inflammatory bowel disease (IBD) usually occurs at young age, and therefore, women IBD patients experience pregnancy during their disease progression. Recently, the use of anti-tumor necrosis factor-α (anti-TNF-α) has been rapidly increasing. The aim of this study was to evaluate pregnancy related outcomes in women with IBD who were treated with anti-TNF-α during pregnancy and immunity of their children.
Methods
Korean women with IBD who had been treated with anti-TNF-α during pregnancy had been enrolled. Medical records were reviewed and a survey was performed for each patient. For the patients who agreed on additional examination for their children, children’s growth, medical history and antibody to hepatitis B surface antigen (anti-HBs) titer were checked.
Results
All 18 patients had been diagnosed with Crohn’s disease. There was not any case of preterm delivery, low birth-weight infant, congenital anomaly, nor stillbirth. All 12 children had followed the regular vaccination schedule for hepatitis B and 4 of them showed negative results for anti-HBs. After the 1 booster vaccination, all children demonstrated seroconversion. Regarding live vaccines, 4 children had bacillus Calmette-Guerin and 4 had rotavirus vaccine before 6 months, without any specific side effects.
Conclusions
This was the first study of immunity of the children born from IBD women who had been treated with anti-TNF-α medication during their pregnancy. IBD women had comparable pregnancy outcomes with the general women population, suggesting that the disease activity rather than the administered medication would be more important in healthy pregnancy. Considering the history of vaccination and anti-HBs titers, immunity seems to be intact in the children.

Citations

Citations to this article as recorded by

Global consensus statement on the management of pregnancy in inflammatory bowel disease
Uma Mahadevan, Cynthia H Seow, Edward L Barnes, María Chaparro, Emma Flanagan, Sonia Friedman, Mette Julsgaard, Sunanda Kane, Siew Ng, Joana Torres, Gillian Watermeyer, Jesus Yamamoto-Furusho, Christopher Robinson, Susan Fisher, Phil Anderson, Richard Gea
Gut.2026; 75(2): 208. CrossRef
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Uma Mahadevan, Cynthia H. Seow, Edward L. Barnes, María Chaparro, Emma Flanagan, Sonia Friedman, Mette Julsgaard, Sunanda Kane, Siew Ng, Joana Torres, Gillian Watermeyer, Jesus Yamamoto-Furusho, Christopher Robinson, Susan Fisher, Phil Anderson, Richard G
American Journal of Gastroenterology.2026; 121(1): 31. CrossRef
How safe are the TNF alpha inhibitors with respect to pregnancy outcomes in autoimmune diseases?
Murali Krishna Moka, Deepalaxmi Rathakrishnan, Sriram. D.K, Melvin George
Reproductive Toxicology.2026; 141: 109202. CrossRef
Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis
Bernardo de Faria Moraes, Gustavo André Pedral Diniz Leite, Luisa Medeiros Visentini, Gabriel André Pedral Diniz Leite, Igor Boechat Silveira, Valbert Oliveira Costa Filho, Luis Pedro Possapp Beis, Leonardo Corrêa Süffert, Pedro Robson Costa Passos, Guilh
Journal of Crohn's and Colitis.2026;[Epub] CrossRef
Safety of Rotavirus Vaccination in Infants That Were Exposed to Biologics In Utero: A Systematic Review
Trevor L Schell, Lucas Fass, Mary E Hitchcock, Francis A Farraye, Mary S Hayney, Sumona Saha, Freddy Caldera
Inflammatory Bowel Diseases.2025; 31(7): 1789. CrossRef
Family Planning and Rheumatoid Arthritis
Catherine Sims, Mehret Birru Talabi
Current Rheumatology Reports.2025;[Epub] CrossRef
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Uma Mahadevan, Cynthia H. Seow, Edward L. Barnes, María Chaparro, Emma Flanagan, Sonia Friedman, Mette Julsgaard, Sunanda Kane, Siew Ng, Joana Torres, Gillian Watermeyer, Jesus Yamamoto-Furusho, Christopher Robinson, Susan Fisher, Phil Anderson, Richard G
Clinical Gastroenterology and Hepatology.2025; 23(11): S1. CrossRef
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Uma Mahadevan, Cynthia H. Seow, Edward L. Barnes, María Chaparro, Emma Flanagan, Sonia Friedman, Mette Julsgaard, Sunanda Kane, Siew Ng, Joana Torres, Gillian Watermeyer, Jesus Yamamoto‐Furusho, Christopher Robinson, Susan Fisher, Phil Anderson, Richard G
Alimentary Pharmacology & Therapeutics.2025; 62(11-12): 1125. CrossRef
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Uma Mahadevan, Cynthia H Seow, Edward L Barnes, María Chaparro, Emma Flanagan, Sonia Friedman, Mette Julsgaard, Sunanda Kane, Siew Ng, Joana Torres, Gillian Watermeyer, Jesus Yamamoto-Furusho, Christopher Robinson, Susan Fisher, Phil Anderson, Richard Gea
Inflammatory Bowel Diseases.2025; 31(10): 2615. CrossRef
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Uma Mahadevan, Cynthia H Seow, Edward L Barnes, María Chaparro, Emma Flanagan, Sonia Friedman, Mette Julsgaard, Sunanda Kane, Siew Ng, Joana Torres, Gillian Watermeyer, Jesus Yamamoto-Furusho, Christopher Robinson, Susan Fisher, Phil Anderson, Richard Gea
Journal of Crohn’s and Colitis.2025;[Epub] CrossRef
Navigating Reproductive Care in Patients With Inflammatory Bowel Disease: A Comprehensive Review
Paula Sousa, Javier P Gisbert, Mette Julsgaard, Christian Philipp Selinger, María Chaparro
Journal of Crohn's and Colitis.2024; 18(Supplement): ii16. CrossRef
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah,
Arthritis & Rheumatology.2023; 75(3): 333. CrossRef
2022 American College of Rheumatology Guideline for Vaccinations in Patients With Rheumatic and Musculoskeletal Diseases
Anne R. Bass, Eliza Chakravarty, Elie A. Akl, Clifton O. Bingham, Leonard Calabrese, Laura C. Cappelli, Sindhu R. Johnson, Lisa F. Imundo, Kevin L. Winthrop, Reuben J. Arasaratnam, Lindsey R. Baden, Roberta Berard, S. Louis Bridges, Jonathan T. L. Cheah,
Arthritis Care & Research.2023; 75(3): 449. CrossRef
Society for Maternal-Fetal Medicine Consult Series #64: Systemic lupus erythematosus in pregnancy
Robert Silver, Sabrina Craigo, Flint Porter, Sarah S. Osmundson, Jeffrey A. Kuller, Mary E. Norton
American Journal of Obstetrics and Gynecology.2023; 228(3): B41. CrossRef
Vaccines in Children Exposed to Biological AgentsIn Uteroand/or During Breastfeeding: Are They Effective and Safe?
Javier P Gisbert, María Chaparro
Journal of Crohn's and Colitis.2023; 17(6): 995. CrossRef
Vaccination for rheumatic diseases: Current issues (based on ACR guidelines)
B. S. Belov, N. V. Muravyeva, E. L. Nasonov
Rheumatology Science and Practice.2023; 61(2): 151. CrossRef
Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases
Soo Min Ahn, Young Bin Joo, Yun Jin Kim, So-Young Bang, Hye-Soon Lee
Journal of Korean Medical Science.2023;[Epub] CrossRef
Modern Ideas about Vaccination of Patients with Rheumatic Diseases: the View of ACR Experts
B. S. Belov, N. V. Muravyeva
Antibiotics and Chemotherapy.2023; 68(5-6): 77. CrossRef
Suboptimal Vaccination Administration in Mothers With Inflammatory Bowel Disease and Their Biologic-Exposed Infants
Helene Chiarella-Redfern, Sangmin Lee, Bellal Jubran, Nastaran Sharifi, Remo Panaccione, Cora Constantinescu, Eric I Benchimol, Cynthia H Seow
Inflammatory Bowel Diseases.2022; 28(1): 79. CrossRef
A systematic review of live vaccine outcomes in infants exposed to biologic disease modifying anti-rheumatic drugs in utero
Bethan Goulden, Nicole Chua, Elaine Parker, Ian Giles
Rheumatology.2022; 61(10): 3902. CrossRef
The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Kristel K Leung, Parul Tandon, Vivek Govardhanam, Cynthia Maxwell, Vivian Huang
Inflammatory Bowel Diseases.2021; 27(4): 550. CrossRef
The Influence of Disease Activity on Pregnancy Outcomes in Women With Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis
Min-A Kim, Young-Han Kim, Jaeyoung Chun, Hye Sun Lee, Soo Jung Park, Jae Hee Cheon, Tae Il Kim, Won Ho Kim, Jae Jun Park
Journal of Crohn's and Colitis.2021; 15(5): 719. CrossRef
Biologics During Pregnancy and Breastfeeding Among Women With Rheumatic Diseases: Safety Clinical Evidence on the Road
Asmaa Beltagy, Azin Aghamajidi, Laura Trespidi, Wally Ossola, Pier Luigi Meroni
Frontiers in Pharmacology.2021;[Epub] CrossRef
ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease
T Kucharzik, P Ellul, T Greuter, J F Rahier, B Verstockt, C Abreu, A Albuquerque, M Allocca, M Esteve, F A Farraye, H Gordon, K Karmiris, U Kopylov, J Kirchgesner, E MacMahon, F Magro, C Maaser, L de Ridder, C Taxonera, M Toruner, L Tremblay, M Scharl, N
Journal of Crohn's and Colitis.2021; 15(6): 879. CrossRef
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
Eric I. Benchimol, Frances Tse, Matthew W. Carroll, Jennifer C. deBruyn, Shelly A. McNeil, Anne Pham-Huy, Cynthia H. Seow, Lisa L. Barrett, Talat Bessissow, Nicholas Carman, Gil Y. Melmed, Otto G. Vanderkooi, John K. Marshall, Jennifer L. Jones
Gastroenterology.2021; 161(2): 669. CrossRef
Canadian Association of Gastroenterology Clinical Practice Guideline for Immunizations in Patients With Inflammatory Bowel Disease (IBD)—Part 1: Live Vaccines
Eric I Benchimol, Frances Tse, Matthew W Carroll, Jennifer C deBruyn, Shelly A McNeil, Anne Pham-Huy, Cynthia H Seow, Lisa L Barrett, Talat Bessissow, Nicholas Carman, Gil Y Melmed, Otto G Vanderkooi, John K Marshall, Jennifer L Jones
Journal of the Canadian Association of Gastroenterology.2021; 4(4): e59. CrossRef
Systematic review with meta‐analysis: risk of adverse pregnancy‐related outcomes in inflammatory bowel disease
Parul Tandon, Vivek Govardhanam, Kristel Leung, Cynthia Maxwell, Vivian Huang
Alimentary Pharmacology & Therapeutics.2020; 51(3): 320. CrossRef
Safety and Optimal Timing of BCG Vaccination in Infants Born to Mothers Receiving Anti-TNF Therapy for Inflammatory Bowel Disease
Sang Hyoung Park, Hyo Jong Kim, Chang Kyun Lee, Eun Mi Song, Sang-Bum Kang, Byung Ik Jang, Eun Soo Kim, Kyeong Ok Kim, Yoo Jin Lee, Eun Young Kim, Yun Jin Jung, Soo-Kyung Park, Dong Il Park, Byong Duk Ye, Sung-Ae Jung, Suk-Kyun Yang
Journal of Crohn's and Colitis.2020; 14(12): 1780. CrossRef
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Drugs.2020; 80(16): 1699. CrossRef

11,005 View
244 Download
27 Web of Science
29 Crossref

Review

IBD

Optimizing the multidimensional aspects of the patient-physician relationship in the management of inflammatory bowel disease: Deborah Chew, Wong Zhiqin, Norhayati Ibrahim, Raja Affendi Raja Ali; Intest Res 2018;16(4):509-521. Published online October 25, 2018; DOI: https://doi.org/10.5217/ir.2018.00074

Abstract PDF PubReader ePub

The patient-physician relationship has a pivotal impact on the inflammatory bowel disease (IBD) outcomes. However, there are many challenges in the patient-physician relationship; lag time in diagnosis which results in frustration and an anchoring bias against the treating gastroenterologist, the widespread availability of medical information on the internet has resulted in patients having their own ideas of treatment, which may be incongruent from the treating physicians’ goals resulting in patient physician discordance. Because IBD is an incurable disease, the goal of treatment is to sustain remission. To achieve this, patients may have to go through several lines of treatment. The period of receiving stepping up, top down or even accelerated stepping up medications may result in a lot of frustration and anxiety for the patient and may compromise the patient-physician relationship. IBD patients are also prone to psychological distress that further compromises the patient-physician relationship. Despite numerous published data regarding the medical and surgical treatment options available for IBD, there is a lack of data regarding methods to improve the therapeutic patient-physician relationship. In this review article, we aim to encapsulate the challenges faced in the patient-physician relationship and ways to overcome in for an improved outcome in IBD.

Citations

Citations to this article as recorded by

Discrepancies between patients’ and gastroenterologists’ perceptions of diagnosis and treatment in ulcerative colitis: a multicenter retrospective study
Zhenzhen Fan, Ruixia Li, Xin Liu, Qian Cao, Weiming Zhu, Minhu Chen, Yihong Fan, Naizhong Hu, Yufang Wang, Xiaoping Lv, Mei Ye, Liangru Zhu, Xiaoyun Yang, Hong Guo, Fang Xiao, Ning Chen, Hongjie Zhang, Yan Chen, Kaichun Wu, Jie Liang
Therapeutic Advances in Gastroenterology.2026;[Epub] CrossRef
Management of inflammatory bowel disease: a holistic approach beyond pharmacotherapy
Najwa F. Mourad, Jana G. Hashash, Viraj C. Kariyawasam, Fadi H. Mourad
Expert Review of Gastroenterology & Hepatology.2025; 19(6): 671. CrossRef
Impact of Psychopathology and Gut Microbiota on Disease Progression in Ulcerative Colitis: A Five-Year Follow-Up Study
Franco Scaldaferri, Antonio Maria D’Onofrio, Elena Chiera, Adrian Gomez-Nguyen, Gaspare Filippo Ferrajoli, Federica Di Vincenzo, Valentina Petito, Lucrezia Laterza, Daniela Pugliese, Daniele Napolitano, Elisa Schiavoni, Giorgia Spagnolo, Daniele Ferrarese
Microorganisms.2025; 13(6): 1208. CrossRef
Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease
Marco Vincenzo Lenti, Maria Lia Scribano, Livia Biancone, Rachele Ciccocioppo, Daniela Pugliese, Luca Pastorelli, Gionata Fiorino, Edoardo Savarino, Flavio Andrea Caprioli, Sandro Ardizzone, Massimo Claudio Fantini, Gian Eugenio Tontini, Ambrogio Orlando,
Frontiers in Medicine.2023;[Epub] CrossRef
Notable gaps between patients’ and physicians’ perspectives on communication and disease management in Japan: multifaceted ad hoc analyses of the global Ulcerative Colitis Narrative Survey for further optimal care
Kenji Watanabe, Sean Gardiner, Shoko Arai
Therapeutic Advances in Gastroenterology.2022;[Epub] CrossRef
Ulcerative Colitis Narrative Global Survey Findings: The Impact of Living With Ulcerative Colitis—Patients’ and Physicians’ View
Marla C Dubinsky, Kenji Watanabe, Pauliina Molander, Laurent Peyrin-Biroulet, Michele Rubin, Gil Y Melmed, J Jasper Deuring, John Woolcott, Joseph C Cappelleri, Kathy Steinberg, Susan Connor
Inflammatory Bowel Diseases.2021; 27(11): 1747. CrossRef
Physician–patient communication affects patient satisfaction in treatment decision-making: a structural equation modelling analysis of a web-based survey in patients with ulcerative colitis
Katsuyoshi Matsuoka, Hirono Ishikawa, Takeo Nakayama, Yusuke Honzawa, Atsuo Maemoto, Fumihito Hirai, Fumiaki Ueno, Noriko Sato, Yutaka Susuta, Toshifumi Hibi
Journal of Gastroenterology.2021; 56(9): 843. CrossRef

19,558 View
150 Download
7 Web of Science
7 Crossref

Statement

IBD

Consensus recommendations for patient-centered therapy in mild-to-moderate ulcerative colitis: the i Support Therapy–Access to Rapid Treatment (iSTART) approach: Silvio Danese, Rupa Banerjee, JR Fraser Cummings, Iris Dotan, Paulo G Kotze, Rupert Wing Loong Leong, Kristine Paridaens, Laurent Peyrin-Biroulet, Glyn Scott, Gert Van Assche, Jan Wehkamp, Jesús K Yamamoto-Furusho; Intest Res 2018;16(4):522-528. Published online October 16, 2018; DOI: https://doi.org/10.5217/ir.2018.00073

Abstract PDF Supplementary Material PubReader ePub

Symptomatic ulcerative colitis (UC) can be a chronic, disabling condition. Flares in disease activity are associated with many of the negative impacts of mild-to-moderate UC. Rapid resolution of flares can provide benefits to patients and healthcare systems. i Support Therapy–Access to Rapid Treatment (iSTART) introduces patient-centered care for mild-to-moderate UC. iSTART provides patients with the ability to self-assess symptomology and self-start a short course of second-line treatment when necessary. An international panel of experts produced consensus statements and recommendations. These were informed by evidence from systematic reviews on the epidemiology, mesalazine (5-ASA) treatment, and patient use criteria for second-line therapy in UC. Optimized 5-ASA is the first-line treatment in all clinical guidelines, but may not be sufficient to induce remission in all patients. Corticosteroids should be prescribed as second-line therapy when needed, with budesonide MMX® being a preferred steroid option. Active involvement of suitable patients in management of UC flares has the potential to improve therapy, with patients able to show good accuracy for flare self-assessment using validated tools. There is a place in the UC treatment pathway for an approach such as iSTART, which has the potential to provide patient, clinical and economic benefits.

Citations

Citations to this article as recorded by

Investigate sodium orthovanadate molecular mechanisms in diabetes-aggravated ulcerative colitis, focusing on Nrf2/Keap1 antioxidant and NF-κB/IL-6 inflammatory pathways
Gurpreet Kaur, Ajay Singh Kushwah
Journal of Molecular Histology.2026;[Epub] CrossRef
Sodium orthovanadate protects against ulcerative colitis and associated liver damage in mice: insights into modulations of Nrf2/Keap1 and NF-κB pathways
Gurpreet Kaur, Ajay Singh Kushwah
Naunyn-Schmiedeberg's Archives of Pharmacology.2025; 398(2): 1557. CrossRef
Synergic effect of combined melatonin and tofacitinib on ameliorating dextran sulfate sodium-induced colitis in rat---role of JAKs/STAT, cell-stress signaling, and inflammatory-immune reaction
Chia-Lo Chang
American Journal of Clinical and Experimental Immunology.2025; 14(4): 185. CrossRef
Probiotics and inflammatory bowel disease: an umbrella meta-analysis of relapse, recurrence, and remission outcomes
Wei Liu, Shengbo Zhang, Changzheng Dong, Xia Lv, Ximin Zheng, Wei Zhao, Mehrdad Jamali, Ranasadat Abedi, Ahmad Saedisomeolia
Nutrition & Metabolism.2025;[Epub] CrossRef
Healing Herbs: A Review of Herbal Treatments for Inflammatory Bowel Disease
Payal N. Vaja, Vivek P. Solanki, Dilip R. Ghusar, Siddhi K. Upadhyay, Harsh H madiya
Asian Journal of Research in Pharmaceutical Sciences.2025; : 381. CrossRef
Management and treatment optimization of patients with mild to moderate ulcerative colitis
Ferdinando D’Amico, Ernesto Fasulo, Vipul Jairath, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
Expert Review of Clinical Immunology.2024; 20(3): 277. CrossRef
Practical management of mild-to-moderate ulcerative colitis: an international expert consensus
Ferdinando D’Amico, Fernando Magro, Axel Dignass, Sameer Al Awadhi, Ana Gutierrez Casbas, Natália Sousa Freitas Queiroz, Grażyna Rydzewska, Byong Duk Ye, Zhihua Ran, Ailsa Hart, Vipul Jairath, Gionata Fiorino, Laurent Peyrin-Biroulet, Silvio Danese
Expert Review of Gastroenterology & Hepatology.2024; 18(8): 421. CrossRef
Framework of IBD Care Delivery Across Ages
Stefan Delen, Susanna Jaghult, Irina Blumenstein, Lieven Pouillon, Peter Bossuyt
Journal of Crohn's and Colitis.2024; 18(Supplement): ii55. CrossRef
Effectiveness of Mesalamine in Patients With Ulcerative Colitis: A Systematic Review
Yurianna Santos, Arturo P Jaramillo
Cureus.2023;[Epub] CrossRef
Encoding bacterial colonization and therapeutic modality by wrapping with an adhesive drug-loadable nanocoating
Huilong Luo, Feng Wu, Xinyue Wang, Sisi Lin, Mengmeng Zhang, Zhenping Cao, Jinyao Liu
Materials Today.2023; 62: 98. CrossRef
iSTART-II: An Update on the i Support Therapy–Access to Rapid Treatment (iSTART) Approach for Patient-Centered Therapy in Mild-to-Moderate Ulcerative Colitis
Ferdinando D’Amico, Fernando Magro, Benedicte Caron, Axel Dignass, Vipul Jairath, Ailsa Hart, Paulo Gustavo Kotze, Kristine Paridaens, Sameer Al Awadhi, Taku Kobayashi, Britta Siegmund, Laurent Peyrin-Biroulet, Silvio Danese
Journal of Clinical Medicine.2023; 12(3): 1142. CrossRef
A review article of inflammatory bowel disease treatment and pharmacogenomics
Nashwa Eltantawy, Islam Abd El-Hamid El-Zayyadi, Ahmed A. Elberry, Layla M. Salah, Mohamed E. A. Abdelrahim, Amira B. Kassem
Beni-Suef University Journal of Basic and Applied Sciences.2023;[Epub] CrossRef
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis
Axel U. Dignass, Kristine Paridaens, Sameer Al Awadhi, Jakob Begun, Jae Hee Cheon, John R. Fullarton, Edouard Louis, Fernando Magro, Juan Ricardo Marquez, Alexander R. Moschen, Neeraj Narula, Grazyna Rydzewska, Simon P. L. Travis
Scandinavian Journal of Gastroenterology.2022; 57(4): 424. CrossRef
Needs and preferences of patients regarding atopic dermatitis care in the era of new therapeutic options: a qualitative study
Linde E. M. de Wijs, Sven van Egmond, Arjan C. A. Devillers, Tamar Nijsten, DirkJan Hijnen, Marjolein Lugtenberg
Archives of Dermatological Research.2022; 315(1): 75. CrossRef
Mesalazine in the induction of clinical and endoscopic remission of mild and moderate ulcerative colitis
M. V. Shapina
Meditsinskiy sovet = Medical Council.2022; (15): 90. CrossRef
Budesonide MMX in the Treatment of Ulcerative Colitis: Current Perspectives on Efficacy and Safety
Giovanni Maconi, Deborah Camatta, Rosanna Cannatelli, Francesca Ferretti, Anna Carvalhas Gabrielli, Sandro Ardizzone
Therapeutics and Clinical Risk Management.2021; Volume 17: 285. CrossRef
High Serum Osmolality May Predict the Disease Severity in Patients with Acute Ulcerative Colitis
Abdussamed VURAL, Aslı VURAL, Selahattin VURAL, Selim TURFAN, Ahmet Cumhur DÜLGER
Online Türk Sağlık Bilimleri Dergisi.2020; 5(2): 324. CrossRef
The Efficacy and Safety of Mesalamine and Probiotics in Mild‐to‐Moderate Ulcerative Colitis: A Systematic Review and Meta‐Analysis
Chunying Tian, Yang Huang, Xiaoxia Wu, Chuhan Xu, Huaien Bu, Hongwu Wang, Jairo Kennup Bastos
Evidence-Based Complementary and Alternative Medicine.2020;[Epub] CrossRef
Teleconsulta en la pandemia por Coronavirus: desafíos para la telemedicina pos-COVID-19
Juan Ricardo Márquez Velásquez
Revista Colombiana de Gastroenterología.2020; 35(Supl. 1): 5. CrossRef
Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
Virginia Solitano, Ferdinando D’Amico, Gionata Fiorino, Kristine Paridaens, Laurent Peyrin-Biroulet, Silvio Danese
Journal of Clinical Medicine.2020; 9(9): 2905. CrossRef
A clinical case of ulcerative colitis in a patient with viral hepatitis
E. D. Kosmachova, M. S. Iakovenko, K. A. Yumukian
South Russian Journal of Therapeutic Practice.2020; 1(3): 95. CrossRef
Case Report on Ulcerative Colitis in 16 year girl
MD.Salma MD.Salma, Y.Siva Y.Siva , , J.Bhargava Narendra , J.Bhargava Narendra
World Journal of Current Medical and Pharmaceutical Research.2020; : 287. CrossRef

15,047 View
590 Download
19 Web of Science
22 Crossref

Original Articles

Colorectal neoplasia

Clinical features and outcomes in spontaneous intramural small bowel hematoma: cohort study and literature review: Eun Ae Kang, Seung Jun Han, Jaeyoung Chun, Hyun Jung Lee, Hyunsoo Chung, Jong Pil Im, Sang Gyun Kim, Joo Sung Kim, Hyuk Yoon, Cheol Min Shin, Young Soo Park, Nayoung Kim, Dong Ho Lee, Hyun Chae Jung; Intest Res 2019;17(1):135-143. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00085

Abstract PDF Supplementary Material PubReader ePub

Background/Aims
Spontaneous intramural small bowel hematoma (SISBH) is an extremely rare complication of anticoagulant or antiplatelet therapy. We assessed the clinical characteristics and outcomes of patients with SISBH according to the anatomical location of the hematoma.
Methods
From January 2003 to February 2016, medical records for all patients hospitalized for SISBH at 2 tertiary referral hospitals were retrospectively reviewed. The primary outcome was requirement for surgery.
Results
A total of 37 patients were enrolled. The mean age was 74.1 years. Among them, 33 patients (89.2%) were taking anticoagulant and/or antiplatelet agents. Duodenal intramural hematoma was detected in 4 patients (10.8%), jejunal in 16 (43.2%), and ileal in 17 (45.9%). Compared to jejunal and ileal involvement, duodenal intramural hematoma was significantly associated with high Charlson comorbidity index and low levels of white blood cells, hemoglobin, and platelets in the blood. SISBH in the duodenum was related to thrombocytopenia in 3 patients following systemic chemotherapy for malignancy. All patients with SISBH showed clinical improvement with conservative therapy. Mean length of hospital stay was 9.35 days. Independent predictors of a hospital stay of more than 7 days were body weight less than 60 kg (odds ratio [OR], 12.213; 95% confidence interval [CI], 1.755–84.998; P=0.011) and a history of cerebrovascular accidents (OR, 6.667; 95% CI, 1.121–39.650; P=0.037).
Conclusions
Compared to jejunal and ileal involvement, thrombocytopenia may result in spontaneous duodenal intramural hematoma among patients who are treated with systemic chemotherapy for malignancies. Patients with SISBH have excellent clinical outcomes with conservative therapy regardless of the anatomical location of the hematoma.

Citations

Citations to this article as recorded by

Duodenal Biopsy Gone Bad: Hematoma, Obstruction, Hemoperitoneum, and Everything Else You Don’t Want
Noemi Zorzetti, Augusto Lauro, Cinzia Baccaro, Giuseppe Ponticelli, Pasquale Ascenzi, Vincenzo Cennamo, Giuseppe Giovanni Navarra
Digestive Diseases and Sciences.2026; 71(2): 427. CrossRef
Drug-Induced Spontaneous Intramural Hematoma of the Gastrointestinal Tract: A Real-World Pharmacovigilance Analysis
Xuehong Wang, Min Luo, Wenyu Li, Yuqian Zhou
Journal of Cardiovascular Pharmacology.2025; 85(4): 297. CrossRef
Idiopathic Duodenal Hematoma: A Case Report and Literature Review
Ebtesam Al-Najjar, Abdullah Esmail, Bayan Khasawneh, Saifudeen Abdelrahim, Maen Abdelrahim
Reports.2025; 8(2): 73. CrossRef
Spontaneous intramural hematoma of the small bowel in anticoagulated patients—Insights into management: A case report
Ali Hajihashemi, Hadi Khanifar, Mahsa Geravandi
Radiology Case Reports.2025; 20(10): 5189. CrossRef
A Case of Direct-Acting Oral Anticoagulant-Induced Intramural Colon Hematoma Successfully Treated by Laparoscopic Surgery
Daisuke Tomita, Shigeo Toda, Ryo Miyazaki, Shuichiro Matoba, Hiroya Kuroyanagi
Cureus.2024;[Epub] CrossRef
Spontaneous Intramural Small Bowel Hematoma in an Elderly Man with Multiple Myeloma
Sigrid L. Williamson, Aishwarya Suresh, Adrian Ong
The American Surgeon™.2023; 89(6): 2816. CrossRef
Intramural duodenal hematoma: diagnosis and management of a rare entity
Álvaro Pérez-Rubio, Juan Carlos Sebastián-Tomás, Sergio Navarro-Martínez, Marta Córcoles Córcoles, Carlos Domingo del Pozo
Cirugía Española (English Edition).2023; 101(7): 515. CrossRef
Hematoma intramural duodenal: diagnóstico y manejo de una entidad infrecuente
Álvaro Pérez-Rubio, Juan Carlos Sebastián-Tomás, Sergio Navarro-Martínez, Marta Córcoles Córcoles, Carlos Domingo del Pozo
Cirugía Española.2023; 101(7): 515. CrossRef
Jejunal intramural haematoma in a captive African lion (Panthera leo)
Richelle G. Butcher, Baukje Lenting, Alison S. Clarke, Kelly Buckle, Cristina Gans
Veterinary Record Case Reports.2023;[Epub] CrossRef
Spontaneous Duodenal Hematoma: A Rare Complication of Triple Antithrombotic Therapy Case Report
Mazin N Habhab, Asad J Torabi, Julie M Clary, George E Revtyak
Future Cardiology.2023; 19(2): 71. CrossRef
Intestinal Spontaneous Intramural Hematoma Secondary to Anticoagulation Therapy: A Case Report
Karim El Aidaoui, Wahib Lahlou, Abderrahim Bourial, Nawal Bouknani, Chafik El Kettani
Cureus.2023;[Epub] CrossRef
Intramural Hematoma of Gastrointestinal Tract in People with Hemophilia A and B
Wei-Jung Teng, Ching-Huei Kung, Mei-Mei Cheng, Jia-Ruey Tsai, Chia-Yau Chang
Journal of Clinical Medicine.2023; 12(9): 3093. CrossRef
Endoscopic management of intramural spontaneous duodenal hematoma: A case report
Giorgio Valerii, Vittorio Maria Ormando, Carlo Cellini, Luca Sacco, Carmelo Barbera
World Journal of Gastroenterology.2022; 28(20): 2243. CrossRef
Warfarin-induced spontaneous intramural small bowel hematoma presenting as an acute abdomen: A case report
Ding-Han Chen, Khay-Seng Soh, Ying-Tso Wang, Te-Chun Shen
Medicine.2022; 101(35): e30335. CrossRef
Spontaneous duodenal haematoma in a patient taking rivaroxaban
Rebeca de Barros Lopes, Finn McLennan Battleday, Toby Calvert, Rob Gwynne‐Jones, Rebecca Thomas
ANZ Journal of Surgery.2021;[Epub] CrossRef
SPONTANEOUS INTRAMURAL SMALL-BOWEL HEMATOMA: A CAUSE OF ACUTE ABDOMEN IN ANTICOAGULATED PATIENTS
Sergio Gil Rojas, Luis Miguel Estela Villa, Elsa María Jiménez Vicente
Revista Española de Enfermedades Digestivas.2021;[Epub] CrossRef
Small Bowel Obstruction
Allison A. Aka, Jesse P. Wright, Teresa DeBeche-Adams
Clinics in Colon and Rectal Surgery.2021; 34(04): 219. CrossRef
Double Trouble: Spontaneous Duodenal Hematoma of Pancreatic Origin
Luísa Martins Figueiredo, David Valadas Horta, Jorge A. Reis
GE - Portuguese Journal of Gastroenterology.2019; 26(6): 458. CrossRef

30,677 View
262 Download
21 Web of Science
18 Crossref

Endoscopy

Clinicopathological feature and treatment outcome of patients with colorectal laterally spreading tumors treated by endoscopic submucosal dissection: Young-Hoon Jeong, Jun Lee, Sang-Wook Kim, Geom-Seog Seo, Hyun-Soo Kim, Young-Eun Joo; Intest Res 2019;17(1):127-134. Published online October 10, 2018; DOI: https://doi.org/10.5217/ir.2018.00075

Abstract PDF PubReader ePub

Background/Aims
Endoscopic submucosal dissection (ESD) is an advanced technique that can be used to treat precancerous and early colorectal neoplasms by facilitating en bloc resection regardless of tumor size. In our study, we investigated the clinicopathological feature and the treatment outcome of patients with colorectal laterally spreading tumors (LSTs) that were treated by ESD.
Methods
The study enrolled all of 210 patients with colorectal LSTs who underwent ESD. Clinical outcomes were analyzed by retrospectively reviewing medical records.
Results
A cancerous pit pattern (Vi/Vn) was more common in pseudo-depressed (PD) subtype than in flat elevated (FE) subtype. The incidence of adenocarcinoma in the PD subtype and nodular mixed (NM) subtypes was significantly higher than in the homogenous (HG) subtype and FE subtype. The en bloc and R0 resection rates were 89.0% and 85.7%, respectively. The bleeding and perforation rates were 5.2% and 1.9%, respectively. The mean procedure time was much longer in the PD subtype than in the FE subtype. The en bloc resection rate was significantly higher in the NM subtype than in the HG subtype. However, there were no statistically significant differences in mean procedure time, en bloc resection rate, R0 resection rate, bleeding rate, or perforation rate between LST-granular and LST-nongranular types.
Conclusions
These results indicate that ESD is acceptable for treating colorectal LSTs concerning en bloc resection, curative resection, and risk of complications. Careful consideration is required for complete resection of the PD subtype and NM subtype because of their higher malignant potential.

Citations

Citations to this article as recorded by

Endoscopic resection of colorectal laterally spreading tumors: Clinicopathologic characteristics and risk factors for treatment outcomes
Li-Hua Guo, Ke-Feng Hu, Min Miao, Yong Ding, Xin-Jun Zhang, Guo-Liang Ye
World Journal of Gastrointestinal Endoscopy.2025;[Epub] CrossRef
Risk factors for unsuccessful colorectal endoscopic submucosal dissection: A systematic review and meta-analysis
Feng Gu, Wei Jiang, Jingyi Zhu, Lei Ma, Boyuan He, Huihong Zhai
Digestive and Liver Disease.2024; 56(8): 1288. CrossRef
Prognosis and risk factors of electrocoagulation syndrome after endoscopic submucosal dissection in the colon and rectum. Large cohort study
Seong-Jung Kim, Su Young Kim, Jun Lee
Surgical Endoscopy.2022; 36(8): 6243. CrossRef
Blue laser imaging combined with JNET (Japan NBI Expert Team) classification for pathological prediction of colorectal laterally spreading tumors
Si-lin Huang, Wen-xin Tan, Qun Peng, Wen-hua Zhang, Hai-tao Qing, Qiang Zhang, Jun Wu, Liang-dou Lin, Zhi-bin Lu, Yu Chen, Wei-guang Qiao
Surgical Endoscopy.2021; 35(10): 5430. CrossRef
Comparison of long-term recurrence-free survival between primary surgery and endoscopic resection followed by secondary surgery in T1 colorectal cancer
Eun Hye Oh, Nayoung Kim, Sung Wook Hwang, Sang Hyoung Park, Dong-Hoon Yang, Byong Duk Ye, Seung-Jae Myung, Suk-Kyun Yang, Chang Sik Yu, Jin Cheon Kim, Jeong-Sik Byeon
Gastrointestinal Endoscopy.2021; 94(2): 394. CrossRef
Second-look endoscopy findings after endoscopic submucosal dissection for colorectal epithelial neoplasms
Soo-kyung Park, Hyeon Jeong Goong, Bong Min Ko, Haewon Kim, Hyo Sun Seok, Moon Sung Lee
The Korean Journal of Internal Medicine.2021; 36(5): 1063. CrossRef

9,712 View
214 Download
7 Web of Science
6 Crossref

Review

IBD

Management of inflammatory bowel disease in older persons: evolving paradigms: Saurabh Kedia, Jimmy K. Limdi, Vineet Ahuja; Intest Res 2018;16(2):194-208. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.194

Abstract PDF PubReader ePub

The incidence and prevalence of inflammatory bowel disease (IBD) is increasing, and considering the aging population, this number is set to increase further in the future. The clinical features and natural history of elderly-onset IBD have many similarities with those of IBD in younger patients, but with significant differences including a broader differential diagnosis. The relative lack of data specific to elderly patients with IBD, often stemming from their typical exclusion from clinical trials, has made clinical decision-making somewhat challenging. Treatment decisions in elderly patients with IBD must take into account age-specific concerns such as comorbidities, locomotor and cognitive function, and polypharmacy, to set realistic treatment targets in order to enable personalized treatment and minimize harm. Notwithstanding paucity of clinical data, recent studies have provided valuable insights, which, taken together with information gleaned from previous studies, can broaden our understanding of IBD. These insights may contribute to the development of paradigms for the holistic and, when possible, evidence-based management of this potentially vulnerable population and are the focus of this review.

Citations

Citations to this article as recorded by

The Crohn's Disease Exclusion Diet Across the Lifespan, Indications and the Globe: An Expert Review Towards Personalized Therapy in Crohn's Disease
Rotem Sigall Boneh, Elena Banci, Luca Scarallo, Marta Herrador‐López, Emma P. Halmos, Dror S. Shouval, Nicolette Wierdsma, Chen Sarbagili‐Shabat, Víctor Manuel Navas‐López, Javier Martín‐de‐Carpi, Yulia Ron, Lindsey Albenberg, Henit Yanai, Franck Carbonne
JCC Plus.2026;[Epub] CrossRef
Older Adults with Inflammatory Bowel Disease Epidemiology in the United States: 2000–2021
Pojsakorn Danpanichkul, Yanfang Pang, Chawinthorn Vuthithammee, Disatorn Dejvajara, Priyata Dutta, Passisd Laoveeravat, Omar Al Ta’ani, Agnes HY. Ho, Chun Wei Pan, Nicole Shu Ying Tang, Kanokphong Suparan, Rashid N. Lui, Donghee Kim, Siew C. Ng, Gursimran
Digestive Diseases and Sciences.2025; 70(7): 2318. CrossRef
Prevalence of metabolic syndrome in patients with inflammatory bowel disease: a meta-analysis on a global scale
Khushbu Viresh Janani, Parsa Saberian, Hardik B. Patel, Narsimha Rao Keetha, Ardalan Etemadzadeh, Anya Patel, Seyyed Mohammad Hashemi, Ehsan Amini-Salehi, Anoop Gurram
Journal of Health, Population and Nutrition.2025;[Epub] CrossRef
Elderly-onset inflammatory bowel disease in Asia: clinical characteristics and therapeutic strategies
Jiyoung Yoon, Daein Kim, You Sun Kim
Intestinal Research.2025; 23(4): 430. CrossRef
Fatigue, sarcopenia, and frailty in older adults with inflammatory bowel disease
Federica BELLONE, Alberto SARDELLA, Marco MUSCIANISI, Giorgio BASILE
Minerva Gastroenterology.2024;[Epub] CrossRef
Histology of IBD and related colitides in the elderly
Giuseppe LEONCINI, Luca REGGIANI-BONETTI, Gloria SIMONCELLI, Vincenzo VILLANACCI
Minerva Gastroenterology.2024;[Epub] CrossRef
Age over sex: evaluating gut microbiota differences in healthy Chinese populations
Jiacheng Wu, Hexiao Shen, Yongling Lv, Jing He, Xiaotian Xie, Zhiyue Xu, Pengcheng Yang, Wei Qian, Tao Bai, Xiaohua Hou
Frontiers in Microbiology.2024;[Epub] CrossRef
Clinical outcomes amongst elderly patients with inflammatory bowel disease
Vithoosharan Sivanathan, Chamara Basnayake, William Connell, Emily Wright, John Nik Ding, Ola Niewadomski, Annalise Stanley, Amy Wilson‐O'Brien, Stephanie Fry, Tamie Samyue, Mark Lust, Emma Flanagan, Alexander J. V. Thompson, Michael A. Kamm
Internal Medicine Journal.2023; 53(10): 1866. CrossRef
Non-neoplastic disorders in an aging gut: concise review
Saurabh Dawra, Pradeep Behl, Sharad Srivastava, Manish Manrai, Alok Chandra, Anupam Kumar, Ankit Kumar, Manveer Singh Tevatia
The Egyptian Journal of Internal Medicine.2023;[Epub] CrossRef
Enfermedad Inflamatoria Intestinal en el adulto mayor: Características clínicas y manejo en un hospital de referencia
Juan Eloy Paredes Méndez, Sonia Irene Pérez Junes, Henry Tomás Vargas Marcacuzco, Edith Melissa Villafuerte Méndez
Revista de Gastroenterología del Perú.2023; 43(1): 13. CrossRef
Clinical spectrum of elderly-onset inflammatory bowel disease in India
Yogesh Kumar Gupta, Arshdeep Singh, Vikram Narang, Vandana Midha, Ramit Mahajan, Varun Mehta, Dharmatma Singh, Namita Bansal, Madeline Vithya Barnaba Durairaj, Amit Kumar Dutta, Ajit Sood
Intestinal Research.2023; 21(2): 216. CrossRef
A new face of old cells: An overview about the role of senescence and telomeres in inflammatory bowel diseases
Michał Sienkiewicz, Kamila Sroka, Agata Binienda, Diana Jurk, Jakub Fichna
Ageing Research Reviews.2023; 91: 102083. CrossRef
Representation and reporting of diverse groups in randomised controlled trials of pharmacological agents in inflammatory bowel disease: a systematic review
Mythili Menon Pathiyil, Anuraag Jena, Arvind Kumar Venkataramana Raju, Tina Aswani Omprakash, Vishal Sharma, Shaji Sebastian
The Lancet Gastroenterology & Hepatology.2023; 8(12): 1143. CrossRef
Relation of geriatric nutritional risk index with clinical risks in elderly‐onset ulcerative colitis
Masaaki Higashiyama, Shunsuke Komoto, Yasuo Suzuki, Mamoru Watanabe, Toshifumi Hibi, Soichiro Miura, Ryota Hokari
Journal of Gastroenterology and Hepatology.2021; 36(1): 163. CrossRef
Atopic dermatitis does not increase the risk of inflammatory bowel disease: A nationwide cohort study
Yu‐Ching Weng, Chao‐Kuei Juan, Hsiu J. Ho, Yi‐Ling Chang, Chun‐Ying Wu, Yi‐Ju Chen
The Journal of Dermatology.2021; 48(2): 168. CrossRef
Common Diarrheal Illnesses in the Elderly
Enad Dawod, Carl V. Crawford
Clinics in Geriatric Medicine.2021; 37(1): 103. CrossRef
Inflammatory Bowel Disease: Managing Complex Patients
Paula Miksa, Shane Ryan Apperley
Physician Assistant Clinics.2021; 6(4): 655. CrossRef
The dietary practices and beliefs of people living with older-onset inflammatory bowel disease
Benjamin Crooks, Ravi Misra, Naila Arebi, Klaartje Kok, Matthew J. Brookes, John McLaughlin, Jimmy K. Limdi
European Journal of Gastroenterology & Hepatology.2021; 33(1S): e442. CrossRef
Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management
G. Pellino, D. S. Keller, G. M. Sampietro, V. Annese, M. Carvello, V. Celentano, C. Coco, F. Colombo, N. Cracco, F. Di Candido, M. Franceschi, S. Laureti, G. Mattioli, L. Pio, G. Sciaudone, G. Sica, V. Villanacci, R. Zinicola, S. Leone, S. Danese, A. Spin
Techniques in Coloproctology.2020; 24(2): 105. CrossRef
Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools
Richard C. Cabot, Eric S. Rosenberg, Virginia M. Pierce, David M. Dudzinski, Meridale V. Baggett, Dennis C. Sgroi, Jo-Anne O. Shepard, Kathy M. Tran, Emily K. McDonald, Tara Corpuz, Hacho B. Bohossian, Emily W. Lopes, Lauren A. Roller, Ashwin N. Ananthakr
New England Journal of Medicine.2020; 382(11): 1042. CrossRef
Elderly-onset vs adult-onset ulcerative colitis: a different natural history?
Irene Zammarchi, Francesco Lanzarotto, Rosanna Cannatelli, Francesca Munari, Federica Benini, Alessandro Pozzi, Alberto Lanzini, Chiara Ricci
BMC Gastroenterology.2020;[Epub] CrossRef
Association between inflammatory bowel disease and bullous pemphigoid: a population-based case–control study
Yi-Ju Chen, Chao-Kuei Juan, Yun-Ting Chang, Chun-Ying Wu, Hsiu J. Ho, Hsiao-Ching Tseng
Scientific Reports.2020;[Epub] CrossRef
Dietary Support in Elderly Patients with Inflammatory Bowel Disease
Piotr Eder, Alina Niezgódka, Iwona Krela-Kaźmierczak, Kamila Stawczyk-Eder, Estera Banasik, Agnieszka Dobrowolska
Nutrients.2019; 11(6): 1421. CrossRef
Exploring the therapeutic potential of sodium benzoate in acetic acid-induced ulcerative colitis in rats
Deepali Walia, Gurpreet Kaur, Amteshwar Singh Jaggi, Anjana Bali
Journal of Basic and Clinical Physiology and Pharmacology.2019;[Epub] CrossRef

13,095 View
196 Download
24 Web of Science
24 Crossref

Original Article

Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and/or thiopurine therapy: a multicenter study from Japan: Shunsuke Komoto, Satoshi Motoya, Yuji Nishiwaki, Toshiyuki Matsui, Reiko Kunisaki, Katsuyoshi Matsuoka, Naoki Yoshimura, Takashi Kagaya, Makoto Naganuma, Nobuyuki Hida, Mamoru Watanabe, Toshifumi Hibi, Yasuo Suzuki, Soichiro Miura, Ryota Hokari; Intest Res 2016;14(2):139-145. Published online April 27, 2016; DOI: https://doi.org/10.5217/ir.2016.14.2.139

Abstract PDF PubReader ePub

<b>Background/Aims</b><br/>

Anti-tumor necrosis factor drugs (anti-TNF) and thiopurines are important treatment options in patients with inflammatory bowel disease (IBD), including during pregnancy. However, there are limited data on the benefit/risk profile of anti-TNF and thiopurines during pregnancy in Asia. The aim of this study was to analyze pregnancy outcomes of female Japanese IBD patients treated with anti-TNF and/or thiopurines.

Methods

This cross-sectional study assessed pregnancy outcomes in 72 women with IBD. Pregnancy outcomes were compared among 31 pregnancies without exposure to infliximab (IFX), adalimumab (ADA), or thiopurines; 24 pregnancies with exposure to anti-TNF treatment (23 IFX, 1 ADA); 7 pregnancies with exposure to thiopurines alone; and 10 pregnancies with exposure to both IFX and thiopurines.

Results

Thirty-five of the 41 pregnancies (85.3%) that were exposed to anti-TNF treatment and/or thiopurines resulted in live births after a median gestational period of 38 weeks. Of the 35 live births, 3 involved premature deliveries; 7, low birth weight; and 1, a congenital abnormality. There were 6 spontaneous abortions in pregnancies that were exposed to anti-TNF treatment (17.7%). Pregnancy outcomes among the 4 groups were similar, except for the rate of spontaneous abortions (P =0.037).

Conclusions

Exposure to anti-TNF treatment or thiopurines during pregnancy was not related to a higher incidence of adverse pregnancy outcomes in Japanese IBD patients except for spontaneous abortion.

Citations

Citations to this article as recorded by

Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis
Bernardo de Faria Moraes, Gustavo André Pedral Diniz Leite, Luisa Medeiros Visentini, Gabriel André Pedral Diniz Leite, Igor Boechat Silveira, Valbert Oliveira Costa Filho, Luis Pedro Possapp Beis, Leonardo Corrêa Süffert, Pedro Robson Costa Passos, Guilh
Journal of Crohn's and Colitis.2026;[Epub] CrossRef
Ulcerative Colitis in Pregnancy: A Japanese Multicenter Cohort Study Focusing on Their Mutual Influence
Yuichi Shimodate, Akiko Shiotani, Ken-ichi Tarumi, Hiroshi Matsumoto, Osamu Handa, Noriaki Tomioka, Naoyuki Nishimura, Kazuhiro Matsueda, Hirokazu Mouri, Motowo Mizuno
Internal Medicine.2025; 64(11): 1633. CrossRef
North American clinical practice guidelines for the medical management of hidradenitis suppurativa in special patient populations
Raed Alhusayen, Serena Dienes, Megan Lam, Afsaneh Alavi, Ali Alikhan, Maria Aleshin, Emad Bahashwan, Steve Daveluy, Noah Goldfarb, Amit Garg, Wayne Gulliver, Tarannum Jaleel, Alexa B. Kimball, Mark G. Kirchhof, Joslyn Kirby, Joi Lenczowski, Hadar Lev-Tov,
Journal of the American Academy of Dermatology.2025; 92(4): 825. CrossRef
A retrospective study of neonatal and pregnancy outcomes in pregnant women suffering from inflammatory arthropathy treated with adalimumab
Navid Najarpour, Elham Rajaei, Karim Mowla, Alireza Ghanbaran
Revista Colombiana de Reumatología.2024; 31(3): 290. CrossRef
Anti-tumor necrosis factor-α therapy may not be safe during pregnancy in women with inflammatory bowel disease: an updated meta-analysis and systematic review
Wei Huang, Xinxing Zhang, Li Zhang, Xiaosong Dai, Heping Chen, Qin Xie
BMC Pregnancy and Childbirth.2024;[Epub] CrossRef
A retrospective study of neonatal and pregnancy outcomes in pregnant women suffering from inflammatory arthropathy treated with adalimumab
Navid Najarpour, Elham Rajaei, Karim Mowla, Alireza Ghanbaran
Revista Colombiana de Reumatología (English Edition).2024; 31(3): 290. CrossRef
The treatment of inflammatory bowel disease with monoclonal antibodies in Asia
Yu Chen, Guolin Zhang, Yuewen Yang, Shuangshuang Zhang, Haozheng Jiang, Kang Tian, Arenbaoligao, Dapeng Chen
Biomedicine & Pharmacotherapy.2023; 157: 114081. CrossRef
Saudi consensus guidance for the management of inflammatory bowel disease during pregnancy
Nahla A. Azzam, Abdulelah Almutairdi, Hajer Y. Almudaiheem, Turki AlAmeel, Shakir A. Bakkari, Othman R. Alharbi, Khalidah A. Alenzi, Maha A. AlMolaiki, Bedor A. Al-Omari, Rayan G. Albarakati, Ahmed H. Al-Jedai, Omar I. Saadah, Majid A. Almadi, Badr Al-Baw
Saudi Journal of Gastroenterology.2023;[Epub] CrossRef
Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis
Ole Haagen Nielsen, John Mark Gubatan, Carsten Bogh Juhl, Sarah Elizabeth Streett, Cynthia Maxwell
Clinical Gastroenterology and Hepatology.2022; 20(1): 74. CrossRef
British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids
Mark D Russell, Mrinalini Dey, Julia Flint, Philippa Davie, Alexander Allen, Amy Crossley, Margreta Frishman, Mary Gayed, Kenneth Hodson, Munther Khamashta, Louise Moore, Sonia Panchal, Madeleine Piper, Clare Reid, Katherine Saxby, Karen Schreiber, Naz Se
Rheumatology.2022;[Epub] CrossRef
Association between Thiopurines Use and Pregnancy Outcomes in Female Patients with Inflammatory Bowel Disease: A Meta-Analysis
Yang Zhang, Dandan Li, Heng Guo, Weina Wang, Xingang Li, Su Shen
Current Pharmaceutical Design.2021; 27(19): 2317. CrossRef
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Anja Geldhof, Jennifer Slater, Michael Clark, Urmila Chandran, Danielle Coppola
Drug Safety.2020; 43(2): 147. CrossRef
The use of biological disease-modifying antirheumatic drugs for inflammatory arthritis in Korea: results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
The Korean Journal of Internal Medicine.2020; 35(1): 41. CrossRef
The Use of Biological Disease-modifying Antirheumatic Drugs for Inflammatory Arthritis in Korea: Results of a Korean Expert Consensus
Eun-Jung Park, Hyungjin Kim, Seung Min Jung, Yoon-Kyoung Sung, Han Joo Baek, Jisoo Lee
Journal of Rheumatic Diseases.2020; 27(1): 4. CrossRef
Maternal and neonatal outcomes associated with biologic exposure before and during pregnancy in women with inflammatory systemic diseases: a systematic review and meta-analysis of observational studies
Nicole W Tsao, Nevena Rebic, Larry D Lynd, Mary A De Vera
Rheumatology.2020; 59(8): 1808. CrossRef
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Drugs.2020; 80(16): 1699. CrossRef
Pregnancy and Neuromyelitis Optica Spectrum Disorder – Reciprocal Effects and Practical Recommendations: A Systematic Review
Rohan D'Souza, Danielle Wuebbolt, Katarina Andrejevic, Rizwana Ashraf, Vanessa Nguyen, Nusrat Zaffar, Dalia Rotstein, Ahraaz Wyne
Frontiers in Neurology.2020;[Epub] CrossRef
Relationship between the Clinical Course of Ulcerative Colitis during Pregnancy and the Outcomes of Pregnancy: A Retrospective Evaluation
Ayumi Ito, Bunei Iizuka, Teppei Omori, Shinichi Nakamura, Katsutoshi Tokushige
Internal Medicine.2018; 57(2): 159. CrossRef
The use of biologics and small molecules in pregnant patients with rheumatic diseases
Maria Gerosa, Lorenza Maria Argolini, Carolina Artusi, Cecilia Beatrice Chighizola
Expert Review of Clinical Pharmacology.2018; 11(10): 987. CrossRef
Long-term clinical outcome after infliximab discontinuation in patients with inflammatory bowel disease
Ji Min Lee, Yoon Jae Kim, Kang-Moon Lee, Hyuk Yoon, Bo-In Lee, Dae Bum Kim, Donghoon Kang
Scandinavian Journal of Gastroenterology.2018; 53(10-11): 1280. CrossRef
Impact of inflammatory bowel disease activity and thiopurine therapy on birth weight: A meta-analysis
Begoña Gonzalez-Suarez, Shreyashee Sengupta, Alan C Moss
World Journal of Gastroenterology.2017; 23(45): 8082. CrossRef
Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases
Naoki Minami, Minoru Matsuura, Yorimitsu Koshikawa, Satoshi Yamada, Yusuke Honzawa, Shuji Yamamoto, Hiroshi Nakase
Intestinal Research.2017; 15(1): 90. CrossRef
Concerns in pregnancy and childbirth of women with inflammatory bowel disease
Sung-Ae Jung
Intestinal Research.2016; 14(2): 107. CrossRef
Common Adverse Effects of Anti-TNF Agents on Gestation
Zacharias Fasoulakis, Panagiotis Antsaklis, Nikolaos Galanopoulos, Emmanuel Kontomanolis
Obstetrics and Gynecology International.2016; 2016: 1. CrossRef

8,906 View
83 Download
27 Web of Science
24 Crossref

First
Prev
Page of 1
Next
Last

Search